U of U Health

No Rating Available?

95 4.4 out of 5 Patient Rating

Languages Spoken: English

Norman L. Foster, M.D., is Professor in the Department of Neurology, Chief of the Division of Cognitive Neurology, Director of the Center for Alzheimer's Care, Imaging and Research (CACIR), and Senior Investigator for the Brain Institute at the University of Utah. He is a member of the Utah Commission on Aging, and a member of the University of Utah Center on Aging steering committee.

Dr. Foster has been nominated by his peers as one of the Best Doctors in America® from 1996 to 2013. He was recognized as a "Health Care Hero" by Utah Business Magazine in 2007 for his clinical innovations at the University of Utah, and he received the ALEXA Award (for a Lifetime of Extraordinary Achievement in Alzheimer’s care and research) from the Utah Chapter of the Alzheimer’s Association in 2010. In 2011, Dr. Foster was appointed as a member of the Utah State Governor’s Alzheimer’s State Plan Task Force.

Dr. Foster received his M.D. from the Washington University School of Medicine in St. Louis. After completing his residency in Neurology at the University of Utah in Salt Lake City, Dr. Foster relocated to Bethesda, Maryland for a three-year fellowship in Experimental Therapeutics with the National Institute of Neurological and Communicative Disorders and Stroke (NINDS) at the NIH.

Dr. Foster was a faculty member of the University of Michigan Department of Neurology for over 20 years. During his tenure, he developed the first clinical program for dementing disorders in the state of Michigan, which eventually formed the nucleus of the Clinical Core of the NIH-funded Michigan Alzheimer’s Disease Research Center, which Dr. Foster directed for the first 16 years of its funding from 1989 to 2005. He also served as Associate Director of the Michigan ADRC from 1994-2004.

Dr. Foster is a Fellow of the American Academy of Neurology, and a chartered member of the Alpha Omega Alpha Honorary Medical Society and the American Neurological Association. He has been a chartered member of the NIH Clinical Neuroscience and Neurodegeneration (CNN) Study Section since 2007, and served as Section Chair from 2010-11.

Dr. Foster’s research focuses primarily on neuroimaging, clinical drug trials, and the clinical pathophysiology of Alzheimer's disease and related dementing disorders. This includes the development and application of brain imaging, especially validating imaging in clinical care. Dr. Foster recently led two multi-center NIH-funded trials of FDG-PET imaging to distinguish Alzheimer’s disease from frontotemporal dementia, which led to a decision by Medicare to fund FDG-PET for this indication. His recent work has shown PET's utility in differentiating between Alzheimer's and frontotemporal dementia, and he is currently validating FDG-PET, amyloid PET and other neuroimaging biomarkers. His group is performing quality assurance and PET analysis as part of the Alzheimer's Disease Neuroimaging Initiative (ADNI), the largest Alzheimer's study ever funded by the NIH. In addition to NIH funding, he is planning a randomized, pragmatic clinical comparative effectiveness trial for the evaluation of patients with both dementia and diabetes that will be submitted to PCORI, the Patient-Centered Outcomes Research Institute. He also has been involved in numerous studies examining the process of evaluating dementia. He is a member of the diagnostic consensus panel for the Aging and Demographics and Memory Study (ADAMS) and was elected by the NIH-funded Alzheimer’s Centers to serve on the committee that developed the Uniform Data Set (UDS) now used at all of the Centers as a basis for evaluation and monitoring longitudinal change in cognition. He is CEO of PAMS, Inc., a University of Utah start-up company developing a mobile application to help family members of individuals with memory concerns. Dr. Foster also has been involved with many clinical trials, including investigator-initiated, NIH-funded, and drug company sponsored drug trials.

Dr. Norman Foster is a board certified geriatric neurologist who has specialized in brain imaging and dementing and neurodegenerative diseases for over 30 years. In 2005, Dr. Foster’s passion for improving Alzheimer's care brought him to the University of Utah, where he helped establish the first academic clinic in the Intermountain West devoted to caring for Alzheimer's disease and related disorders – the Center for Alzheimer's Care, Imaging and Research (CACIR).

Dr. Foster sees patients in CACIR’s sub-specialty Cognitive Disorders Clinic. His clinical interests include a broad spectrum of neurodegenerative diseases, including Alzheimer’s disease, frontotemporal dementia, and dementia that is atypical, rapidly progressive, early-onset, focal, or familial.

Dr. Foster also conducts extensive research in cognitive neurology and brain imaging.

Clinical Locations

801-585-7575

Academic Departments	Neurology - Professor Surgery - Adjunct Professor
Academic Divisions	Cognitive Neurology Otolaryngology-Head and Neck Surgery
Board Certification	American Board of Psychiatry & Neurology (Neurology) United Council for Neurologic Subspecialties (Geriatric Neurology)

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Learn About Our Survey

Likelihood of recommending care provider

4.4/ 5

Care provider spoke using clear language

4.6/ 5

Care provider's explanation of condition/problem

4.5/ 5

My confidence in care provider

4.5/ 5

Care provider's effort to include me in decisions

4.3/ 5

Wait time at clinic

3.7/ 5

Time care provider spent with me

4.3/ 5

Care provider's concern for questions & worries

4.4/ 5

Care provider's friendliness and courtesy

4.5/ 5

Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

UofU Patient
March 24, 2019
Very happy with time spent with Dr. but often cut me off when talking. Was surprised at how much time he did spend with us. Often felt as though I was being told what "I should have done". Isn't hindsight wonderful!

UofU Patient
March 12, 2019
Dr. Foster went out of his way to provide answers to questions and provide resources for further study

UofU Patient
March 11, 2019
it took toolong for little information

UofU Patient
March 04, 2019
Medical assistant, Rachel, was very friendly and helpful. We enjoyed interacting with her. Dr. Hoevensten (sp?) was very warm, engaging and made us feel very comfortable. Dr. Foster is a bit more distant in his patient approach, but is obviously very experienced. It is not easy to hear the diagnosis he had to give and I am sure it is not easy for him to give it!

UofU Patient
January 16, 2019
Very good

UofU Patient
December 14, 2018
good

UofU Patient
November 20, 2018
Dr . Foster is always great. This time he had a student, ( called herself a fellow /intern) and she was very good and helpful as well. Very interested and eager to help. I cant remember her name. From Montana. The girl that did the cognitive test were also very good. All the staff seems to make all the patients comfortable and relaxed as best as they can.

UofU Patient
November 04, 2018
Dr. Foster spent a lot of time with us and answered all of my questions. I had researched my husband's condition, and when I brought up some of that with Dr. Foster, he was very willing to discuss how the information I had found applied to my husband's individual case. Dr. Foster was respectful, knowledgeable, and helpful. I pushed for clarification on a couple of items, and he patiently explained his position. Overall, I am very pleased with the care we received and interaction we had with Dr. Foster.

UofU Patient
October 30, 2018
An nurse assistant came first, then a resident doctor with a trainee doctor from BYU? and finally, Dr. Foster. Is this the standard? Do we then end up pay separately for all these people, when we only signed up for Dr. Foster? I understand the nurse assistant who did yet another assessment, the very same given when I visited, Dr. Duff & Dr. Hammers, and now again. Dr. Foster came into the visit for 15 minutes if that and said, "well, the results are all consistent". And then done!!!! I'm not sure why I'll be paying a lot of money for this visit for just that from the doctor that I was scheduled to see. Disappointing.

UofU Patient
October 15, 2018
Doctor was way behind schedule due to shortage other doctors and had to hurry

UofU Patient
October 15, 2018
It was a very packed day and the staff did an en excellent job to manage a"filled" day.

UofU Patient
September 27, 2018
We always are able to spend adequate time with doctors. In CA doctors always seem to be in a hurry which is definitely not the case at the U of U

UofU Patient
September 23, 2018
Everything is good except the original time it took to get the first appointment.

UofU Patient
August 20, 2018
Resident and intern where also first class

UofU Patient
June 25, 2018
we spent the first two hours with physician assistant and only 10 min with the dr. he came in, went over what they had observed and what new scans we needed. we had a few questions and he said: i have other patients to see so i got to go. follow me to the front to check out??? felt very rushed hope he will be better after we have the new scans done.

UofU Patient
June 02, 2018
No bad experiences

UofU Patient
May 08, 2018
All the staff is always 100 % great with us. They always seem to treat all patients and family with great respect and patience.

UofU Patient
May 07, 2018
MD looked at his pager, said he had another patient, did not discuss meds, side effects. LCSW was great. She was informative, pleasant, not in a hurry and said to call with questions. This was the first visit with the MD and then the LCSW when the diagnosis was presented.

UofU Patient
May 04, 2018
i have already referred a business associate to Dr Foster

UofU Patient
March 16, 2018
Dr. Foster is the best!

UofU Patient
March 12, 2018
Provider was patient and willing to explain, listen to opinions, questions.

UofU Patient
February 24, 2018
Dr. Foster took a lot of time explaining the diagnosis and how he came to that conclusion.

UofU Patient
February 19, 2018
He was great once he got into the room. Maybe you should look at scheduling appointments further apart.

UofU Patient
February 19, 2018
Resident was particularly good. Great personality, voice and professionalism. Dr Foster is always a superstar.

UofU Patient
February 14, 2018
Dr. Foster is very knowledgeable and skilled. Also caring.

UofU Patient
December 06, 2017
Too much technical jargon.

UofU Patient
December 04, 2017
All care providers seemed considerate. Dr. Foster was verbally/socially moving at a speed I had difficulty keeping up with.

UofU Patient
November 08, 2017
the providers were very very good.

UofU Patient
November 07, 2017
Too early for decisions and meds. Dr. Foster provided the best explanation of events from _____ history we have heard. Gave me (wife) lots of confidence. _____ liked Dr. Foster.

UofU Patient
September 05, 2017
good

UofU Patient
September 02, 2017
we're finally getting the help we need. thank you U of U

UofU Patient
August 31, 2017
we felt very confident in my dad's diagnosis. the Dr really put us at ease.

UofU Patient
August 21, 2017
he just keep getting beeped for another patient so i maybe had 15 min and with him so I left with questions unanswered so he could get to another patient even my husband was shocked at how fast it was.

UofU Patient
August 05, 2017
I appreciate a written summary of information that we talked about with Dr Foster. Thank you

UofU Patient
August 05, 2017
I can't say enough positives about Dr. Foster. It has been such a relief to speak and ask questions about PSP to someone who understands the disease as well as it can be understood and explain our situation to the point I now have information specific to my husband. I am SO thankful for my sister _____ and brother-in-law, _____ for recommending him to us.

UofU Patient
July 09, 2017
I am a retired professional and tend to interact with MDs and staff on an even level. In this office, they respond in kind and communication is excellent!

UofU Patient
June 09, 2017
Dr. Foster is really good at what he does, we are pleased with his advice. he is not good about the medications, but he recommended geriatric psychology for mom's dementia.

UofU Patient
May 27, 2017
Dr Foster was concerned that done if his explanations we're difficult for us to understand so he sent us to Liz Garcia-Leavitt for extra classification. Thru went above and beyond.

UofU Patient
May 15, 2017
The care provider didn't explain why he didn't need to see us anymore. I walked aware wondering what was going on.

UofU Patient
May 08, 2017
excellent staff

UofU Patient
May 08, 2017
Again, this was more routine than specific. I really wasn't in need of support or encouragement or explanations.

UofU Patient
April 16, 2017
Dr Foster is going to be a great help in diagnosing and caring for my husband. I'm grateful we have him on our side

UofU Patient
April 14, 2017
Dr Foster is exceptional!

UofU Patient
March 17, 2017
Dr. Foster was friendly and very knowledgeable. He had much information and good suggestions for us. His assistance was a very good, too.

UofU Patient
March 13, 2017
We did not receive instructions regarding follow up care and nothing new regarding medications.

UofU Patient
February 02, 2017
Couldn't have been a better experience with the care provider.

UofU Patient
November 04, 2016
I was certainly apprehensive on my first visit but the staff and Drs. quickly put me at ease. I would recommend this clinic to my family and friends.

UofU Patient
October 07, 2016
Dr. Foster and Staff are awesome!

UofU Patient
August 31, 2016
We have been impressed with the time spent making sure we understood.

UofU Patient
August 09, 2016
we are greatfull we have such a competent Doctor

UofU Patient
June 17, 2016
dr foster is a pleasure to work with

UofU Patient
June 08, 2016
I was impressed that Dr. Foster was well informed regarding my husband's history and study results. He took the time to explain findings, his impressions, drug interactions, and recommendations. We look forward to working with him in the future.

UofU Patient
May 08, 2016
This was about previously diagnosed Alzhiemer's . It was really sort of "following progression" session. Medications, for example, just weren't at issue.

UofU Patient
May 08, 2016
Just barely getting to know the new care provider. I'm assuming the 'good' marks will turn to 'excellent' when I get to know him better

UofU Patient
March 15, 2016
Dr. Foster was very knowledgeable, kind, responsive to my questions, and helpful.

UofU Patient
March 15, 2016
Great!

UofU Patient
March 03, 2016
I appreciated the contact made as I was leaving which enabled me to meet with another provider regarding a special program possibility.

UofU Patient
February 29, 2016
Everyone we met with was very kind, helpful, and concerned.

UofU Patient
February 27, 2016
good

UofU Patient
February 26, 2016
Dr. Foster is always concerned and real. He doesn't sugar-coat things and explains them well. I appreciate his sincerity and his professionalism. He is a dedicated professional who cares about his patients.

UofU Patient
February 16, 2016
a good visit. the diagnosis was upgraded and explained well

UofU Patient
October 05, 2015
I UNDERSTAND DR. FOSTER IS EXTREMELY BUSY, BUT MY WIFE IS IN AN EXTREMELY FRAGIL STATE. BUT HAVING TO WAITE "TWO MONTHS" TO DO ANY DEFINITIVE TESTING AFTER BEING TOLD THAT SHE HAS SOME SIGNIFICANT COGNITIVE ISSUES IN PLACE, IS EXTREMELY UPSETTING TO MY WIFE. THEN AFTER THIS TESTING IS DONE, HAVING TO WAITE ANOTHER MONTH TO SEE DR. FOSTER HAS TOTALLY UN- DONE HER AND SHE IS BECOMING INCREASINGLY DEPRESSED NOT KNOWING WHAT LIES AHEAD.

UofU Patient
September 23, 2015
The Dr and all the staff were all great. However, we can't get in for a follow-up with the Dr until jan which is 4 months from the initial appt. That is a ridiculous time frame, especially since we are supposed to wait until then to get the results of labwork and MRI that is being done in sept. The tests will help determine the diagnosis which means we have to wait 4 months to understand what course of care will be recommended. This is not acceptable. They could at least have a resident follow up with us, if the dr is too booked up.

UofU Patient
September 07, 2015
Dr. Foster was very helpful, and Dr. Keown was excellent in doing the neurological exam.

UofU Patient
August 08, 2015
I left the office feeling that was given appropriate information and diagnosis.

UofU Patient
August 03, 2015
It is always a positive experience when we leave after seeing Dr. Norman Foster

UofU Patient
June 15, 2015
The nurses with first rate (very good) at establishing rapport and the doctor was immediately addressing my concerns and correctly evaluated my knowledge base and ability to understand. Actually, at one point I got up and hugged him because he was completely in tune with my concerns, goals and plan for myself.

UofU Patient
February 09, 2015
Visit was not rushed, all our concerns were addressed, overall avery pleasant experience.

UofU Patient
January 27, 2015
the med tech moved thru the first diagnostic too quickly. The other staff were wonderful. Dr Foster,spent time explaining care, concerns and what to expect.i greatly appreciated his help in providing information that was clear and understandable..

UofU Patient
January 26, 2015
First time seeing Dr. Foster. He wants more tests done.

UofU Patient
July 18, 2014
I felt very comfortable with Dr. Foster... He is a very kind man... And he comes across as being very concerned about me, and I'm sure that he is that way with all of his patients...

UofU Patient
June 16, 2014
did not seem very organized and not sure he had all the test results from all the tests. This is a guess, but it seemed that way to me.

UofU Patient
May 19, 2014
after a few brief questions, I was told I probably had Alzheimer's . I'm sure you see many patients but I left feeling like I was doomed after such a brief exam.

UofU Patient
April 06, 2014
Once again we are very lucky to have Norman Foster as a doctor

UofU Patient
March 28, 2014
seem their biggest concern was how good our health insurance was

UofU Patient
February 03, 2014
some uncertainty as who would talk to primary care provider about Rx recommendations.

UofU Patient
January 12, 2014
we like Dr Foster- he presents a very personal, encouraging & caring relationship

UofU Patient
November 14, 2013
Good

UofU Patient
August 19, 2013
We left with no idea of how to proceed; why we needed another mri; just treatment ideas and information etc. We may consult another physician.

UofU Patient
July 31, 2013
Dr Foster appears to be very experienced in dealing with the type of medical problems that my uncle is presenting. Sometimes we wonder what difference it could have made if we had had the chance to have seen him a year or two prior (with hindsight!).

UofU Patient
May 29, 2013
The clinic is excellent in sharing a scary diagnosis in a candid yet compassionate manner. I am grateful for both.

UofU Patient
May 07, 2013
Dr Foster is awesome!

UofU Patient
April 22, 2013
I would recommend the staff to all. They are great

UofU Patient
April 04, 2013
Patient did not feel like she was included in the discussion. Dr. Foster spoke with family instead of directing the conversation to her. She indicated that she felt like a illness instead of a person when he was directing teaching to resident (?).

UofU Patient
March 04, 2013
I believe should have provided more information about what the initial testing revealed. A little bit condescending.

UofU Patient
November 07, 2012
We felt comfortable with the counsel and direction Dr Foster gave to us. We value his expertise and know we are on the right track if we follow his advise.

UofU Patient
October 22, 2012
Dr Foster was awesome. Obviously knows what he is doing and instills confidence. My wife is looking forward to her next visit with him when he expects to confirm with her what is going on. She is comfortable with whatever the outcome is.

UofU Patient
October 18, 2012
dr. foster was very helpful in sorting out my memory loss problem.

UofU Patient
October 08, 2012
We feel we had the very best of care

UofU Patient
October 04, 2012
We had not received the notes from the first visit so we were not fully prepared for the discussion. Dr. Foster had to take more time explaining all of those things at the onset of the discussion. This took up more of his time. He did not seem to rush over anything even though this took longer.

UofU Patient
September 20, 2012
The doctor had a tendency to speak in doctor jargon which was a bit hard to understand. However he was very polite.

UofU Patient
August 09, 2012
Dr. Foster was very personable. He made us feel comfortable about the next steps and required testing for her condition. She was very at ease with him.

UofU Patient
May 21, 2012
Dr Foster has a way of providing pertinent information in a positive way that we can understand. We feel he is sincerely concerned, and highly qualified in his field. We appreciate the care we've received. The care goes beyond diagnosis, to include ways of coping, in a proactive format before needs arise.

UofU Patient
March 19, 2012
We both feel comfortable with the doctor and his team and have extremely high confidence in his capacity and desire to help.

UofU Patient
January 23, 2012
good

Dr. Foster also conducts extensive research in cognitive neurology and brain imaging.

Academic Locations

801-587-7236

Academic Departments	Neurology - Professor Surgery - Adjunct Professor
Academic Divisions	Cognitive Neurology Otolaryngology-Head and Neck Surgery
Board Certification	American Board of Psychiatry & Neurology (Neurology) United Council for Neurologic Subspecialties (Geriatric Neurology)

Neurodegenerative Disorders
Alzheimer's Disease
Brain Imaging
Frontotemporal Dementia
PET Markers in Dementia

Fellowship	National Institute of Neurological & Communicative Disorders Medical Therapeutics Fellow
Residency	University of Utah School of Medicine Neurology Resident
Internship	Jewish Hospital of St. Louis, Washington Univ Medical Center Medicine Intern
Professional Medical	Washington University Medicine M.D.
Undergraduate	MacMurray College Biology and Chemistry B.A.

Journal Article

Perry W, Lacritz L, Roebuck-Spencer T, Foster N, et al (). Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. https://doi.org/10.1093/geroni/igy025. Innov Aging, 2(2, Jun 18), igy025.
Perry W, Lacritz L, Roebuck-Spencer T, Foster N, et al (). Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. doi:10.1093/arclin/acy052. Arch Clin Neuropsychol, 33(6), 655-675.
Perry W, Lacritz L, Roebuck-Spencer T, Foster N, et al (). Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. doi: 10.1080/13854046.2018.1517503. Clin Neuropsychol, 32(7), 1193-1225.
Messner DA, Rabins P, Downing AC, Irizarry M, Foster NL, et al (). Designing Preclinical Trials of Disease Modifying Agents forAlzheimer’s Disease: What Evidence is Meaningful to Patients, Providers, and Payers? doi: http://dx.doi.org/10.14283/jpad.2018.42. J Prev Alzheimers Dis, (Nov 2018), 1-7.
Egan MF, Kost J, Tariot PN, et al (). Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer's Disease. N Engl J Med, 2018(378), 1691-1703.
King JB, Jones KG, Goldberg E, Rollins M, MacNamee K, Moffit C, Naidu SR, Ferguson MA, Garcia-Leavitt E, Amaro J, Breitenbach KR, Watson JM, Gurgel RK, Anderson JS, Foster NL (). Increased Functional Connectivity After Listening to Favored Music in Adults With Alzheimer Dementia. http://dx.doi.org/10.14283/jpad.2018.19. J Prev Alzheimers Dis, 6(1), 56-62.
Hammers DB, Atkinson TJ, Dalley BC, Suhrie KR, Beardmore BE, Burrell LD, Horn KP, Rasmussen KM, Foster NL, Duff K, Hoffman JM (). Relationship between 18F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults. Clin Neuropsychol, 31(3), 531-543.
Morehead K, Dunlosky J, Foster NL (). Do people use category-learning judgments to regulate their learning of natural categories? Mem Cognit, 45(8), 1253-1269.
Duff K, Hammers DB, Dalley BCA, Suhrie KR, Atkinson TJ, Rasmussen KM, Horn KP, Beardmore BE, Burrell LD, Foster NL, Hoffman JM (). Short-Term Practice Effects and Amyloid Deposition: Providing Information Above and Beyond Baseline Cognition. J Prev Alzheimers Dis, 4(2), 87-92.
Ganz ML, Tawah AF, Guo S, Chitnis AS, Silies H, Schuble B, Jovalekic A, Foster NL (). The impact of β-amyloid positron emission tomography on the diagnostic and treatment decisions of dementia experts. Neurodegener Dis Manag, 7(2), 107-117.
Duff K, Horn KP, Foster NL, Hoffman JM (2015 May). Short-Term Practice Effects and Brain Hypometabolism: Preliminary Data from an FDG PET Study. Arch Clin Neuropsychol, 30(3), 264-70.
Kotagal V, Langa KM, Plassman BL, et al (). Factors associated with cognitive evaluations in the United States. Neurology, 84, 64-71.
Jagust WJ, Lahdau SM, Koeppe RA, Reiman EM, Chen K, Mathis C, Price, JC, Foster NL, Wang AY (). The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015. Alzheimer's & Dementia, 11, 757-771.
Martin, MM, Rothwell, EW, Venne VL, Foster, NL (). Perceptions of tissue storage in a dementia population among spouses and offspring. J Genet Couns, 24(3), 503-11.
Toledo JB, Bjerke M, Da X, Landau SM, Foster NL, Jagust W, Jack C Jr, Weiner M, Davatzikos C, Shaw LM, Trojanowski JQ, ADNI (). Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β-Amyloid Measures Across the Spectrum of Alzheimer Disease. JAMA Neurol, 72(5), 571-81.
Schmidt ME, Chiao P, Klein G, Matthews D, Thurfjell L, Cole PE, Margolin R, Landau S, Foster NL, Mason NS, De Santi S, Suhy J, Koeppe RA, Jagust W (2015 Sep). The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data. Alzheimer's & Dementia, 11(9), 1050-68.
Witte MW, Foster NL, Fleisher AS, Williams MW, Quaid K, Wasserman M, Hunt G, Roberts JS, Rabinovici G, Levenson JL, Hake AM, Hunter CA, VanCampen LE, Pontecorvo MJ, Hochstetler HM, Tabas LB, Trzepacz PT (). Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations. Alzheimer's & Dementia, 1(3), 358-367.
Puig K, Lutz B, Urquhart S, Rebel A, Zhou X, Manocha G, Sens M, Tuteja A, Foster NL, Combs C (). "Overexpression of Mutant Amyloid Precursor Protein and Presenilin 1 Modulates Enteric Nervous System". J Alzheimers Dis, 44(4), 1263-78.
Duff K, Foster NL, Hoffman J (). Practice effects and amyloid deposition: Preliminary data on a method for enriching samples in clinical trials. Alzheimer Dis Assoc Disord, Jul-Sep(3), 247-52.
Foster NL, Hackett J, White G, Chenevery S, Svarvar P, Bain L, Carillo M (). Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence. Alzheimer's & Dementia, 10, 503-508.
Foster NL, Mottola K, Hoffman J (). Coverage With Evidence Development What To Consider. JAMA Neurol, 71(4), 399-400.
Gurgel R, Ward P, Schwartz S, Norton M, Foster NL, Tschanz J (). Relationship of Hearing Loss and Dementia: A Prospective, Population-Based Study. Otol Neurotol, 35, 775-781.
Grim K, Hammers D, Wang A, Foster NL (). P25 Neuropsychological Test Performance Predicts Abnormal FDG-PET Metabolism. J Am Geriatr Soc, 62(s1), S10-S11.
Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH (2013 Mar). Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med, 54(3), 476-90.
Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Carrillo MC, Hartley DM, Hedrick S, Pappas V, Thies WH (2013 Jan). Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimer's & Dementia, 9(1), e-1-16.
Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM (2013 Jul). Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med, 54(7), 1011-3.
Johnson KA, Minoshima S, Bohnen NI, Donohoe KJ, Foster NL, Herscovitch P, Karlawish JH, Rowe CC, Hedrick S, Pappas V, Carrillo MC, Hartley DM (2013 Jul). Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging. Alzheimer's & Dementia, 9(4), e106-9.
Duff K, Foster NL, Dennett K, Hammers DB, Zollinger LV, Christian PE, Butterfield RI, Beardmore BE, Wang AY, Morton KA, Hoffman JM (2013 Nov). Amyloid deposition and cognition in older adults: the effects of premorbid intellect. Arch Clin Neuropsychol, 28(7), 665-71.
Kauwe JS, Ridge PG, Foster NL, Cannon-Albright LA (2013). Strong evidence for a genetic contribution to late-onset Alzheimer's disease mortality: a population-based study. PLoS ONE, 8(10), e77087.
Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ, the Alzheimers Disease Neuroimaging Initiative (). Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging, 32(7), 1207-18.
Jack CR Jr, Barkhof F, Bernstein MA, Cantillon M, Cole PE, Decarli C, Dubois B, Duchesne S, Fox NC, Frisoni GB, Hampel H, Hill DL, Johnson K, Mangin JF, Scheltens P, Schwarz AJ, Sperling R, Suhy J, Thompson PM, Weiner M, Foster NL (2011 Jul). Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's & Dementia, 7(4), 474-485.e4.
Schenkenberg T, Foster NL, Bromberg MB, DeWitt LD, Flanigan KM (2011 Aug 16). Neurology Academic Advisory Committee: a strategy for faculty retention and advancement. Neurology, 77(7), 684-90.
Plassman BL, Langa KM, McCammon RJ, Fisher GG, Potter GG, Burke JR, Steffens DC, Foster NL, Giordani B, Unverzagt FW, Welsh-Bohmer KA, Heeringa SG, Weir DR, Wallace RB (). Incidence of Dementia and Cognitive Impairment Not Dementia in the United States. Ann Neurol, 70(3), 418-26.
Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, Lee W, Liu X, Bandy D, Alexander GE, Thompson PM, Shaw L, Trojanowski JQ, Jack CR Jr, Landau SM, Foster NL, Harvey DJ, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM, Alzheimers Disease Neuroimaging Initiative (). Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage, 56(1), 52-60.
Womack KB, Diaz-Arrastia R, Aizenstein HJ, Arnold SE, Barbas NR, Boeve BF, Clark CM, Decarli CS, Jagust WJ, Leverenz JB, Peskind ER, Turner RS, Zamrini EY, Heidebrink JL, Burke JR, Dekosky ST, Farlow MR, Gabel MJ, Higdon R, Kawas CH, Koeppe RA, Lipton AM, Foster NL (). Temporoparietal Hypometabolism in Frontotemporal Lobar Degeneration and Associated Imaging Diagnostic Errors. Arch Neurol, 68(3), 329-37.
Gabel MJ, Foster NL, Heidebrink JL, Higdon R, Aizenstein HJ, Arnold SE, Barbas NR, Boeve BF, Burke JR, Clark CM, Dekosky ST, Farlow MR, Jagust WJ, Kawas CH, Koeppe RA, Leverenz JB, Lipton AM, Peskind ER, Turner RS, Womack KB, Zamrini EY (). Validation of consensus panel diagnosis in dementia. Arch Neurol, 67(12), 1506-12.
Wu X, Chen K, Yao L, Ayutyanont N, Langbaum JB, Fleisher A, Reschke C, Lee W, Liu X, Alexander GE, Bandy D, Foster NL, Thompson PM, Harvey DJ, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM, Alzheimers Disease Neuroimaging Initiative (). Assessing the reliability to detect cerebral hypometabolism in probable Alzheimer's disease and amnestic mild cognitive impairment. J Neurosci Methods, 192(2), 277-85.
Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR Jr, Weiner MW, Jagust WJ, Alzheimers Disease Neuroimaging Initiative (). Comparing predictors of conversion and decline in mild cognitive impairment. Neurology, 75(3), 230-8.
Chen K, Langbaum JBS, Fleisher AS, Ayutyanont N, Reschke C, Lee W, Liu X, Bandy D, Alexander GE, Thompson PM, Foster NL, Harvey DJ, de Leon MJ, Koeppe RA, Jagust WJ, Weiner MW, Reiman EM, and The Alzheimers Disease Neuroimaging Initiative (). Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: Findings from the Alzheimer's Disease Neuroimaging Initiative. Neuroimage, 51(2), 654-64.
Jagust WJ, Bandy D, Chen K, Foster NL, Landau SM, Mathis CA, Price JC, Reiman EM, Skovronsky D, Koeppe RA, Alzheimers Disease Neuroimaging Initiative (). The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimer's & Dementia, 6(3), 221-9.
Langbaum JB, Chen K, Lee W, Reschke C, Bandy D, Fleisher AS, Alexander GE, Foster NL, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM (2009 May 1). Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage, 45(4), 1107-16.
Weintraub S, Salmon D, Mercaldo N, Ferris S, Graff-Radford NR, Chui H, Cummings J, DeCarli C, Foster NL, Galasko D, Peskind E, Dietrich W, Beekly DL, Kukull WA, Morris JC (2009 Apr-Jun). The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery. Alzheimer Dis Assoc Disord, 23(2), 91-101.
Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, Foster NL, Petersen RC, Weiner MW, Price JC, Mathis CA (2009 Oct 13). Relationships between biomarkers in aging and dementia. Neurology, 73(15), 1193-9.
Foster NL, Andersen TC, Zamrini EY (2009). Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Innovations in care that advance Alzheimer's disease drug development. Alzheimer's & Dementia, 5(2), 159-62.
Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA (2008 Jan). Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimer's & Dementia, 4(1 Suppl 1), S29-36.
Habeck C, Foster NL, Perneczky R, Kurz A, Alexopoulos P, Koeppe RA, Drzezga A, Stern Y (2008 May 1). Multivariate and univariate neuroimaging biomarkers of Alzheimer's disease. Neuroimage, 40(4), 1503-15.
Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S (2007 Oct). FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 130(Pt 10), 2616-35.
Awate SP, Tasdizen T, Foster N, Whitaker RT (). Adaptive Markov modeling for mutual-information-based, unsupervised MRI brain-tissue classification. Med Image Anal, 10(5), 726-39.
Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, Galasko D, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, Kukull WA (2006 Oct-Dec). The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord, 20(4), 210-6.
Higdon R, Foster NL, Koeppe RA, DeCarli CS, Jagust WJ, Clark CM, Barbas NR, Arnold SE, Turner RS, Heidebrink JL, Minoshima S (2004 Jan 30). A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging. Stat Med, 23(2), 315-26.
Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ (2004 Jan). Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol, 61(1), 59-66.
Moretti P, Lieberman AP, Wilde EA, Giordani BI, Kluin KJ, Koeppe RA, Minoshima S, Kuhl DE, Seltzer WK, Foster NL (2004 May 25). Novel insertional presenilin 1 mutation causing Alzheimer disease with spastic paraparesis. Neurology, 62(10), 1865-8.
Banaszak-Holl J, Fendrick AM, Foster NL, Herzog AR, Kabeto MU, Kent DM, Straus WL, Langa KM (2004 Apr-Jun). Predicting nursing home admission: estimates from a 7-year follow-up of a nationally representative sample of older Americans. Alzheimer Dis Assoc Disord, 18(2), 83-9.
Langa KM, Larson EB, Wallace RB, Fendrick AM, Foster NL, Kabeto MU, Weir DR, Willis RJ, Herzog AR (2004 Apr-Jun). Out-of-pocket health care expenditures among older Americans with dementia. Alzheimer Dis Assoc Disord, 18(2), 90-8.
Singer C, Tractenberg RE, Kaye J, Schafer K, Gamst A, Grundman M, Thomas R, Thal LJ, for the Alzheimers Disease Cooperative Study Foster NL, et al (2003). A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep, 26, 893-901.
Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas R, Thal L, for the Alzheimers Disease Cooperative Study Foster NL, et al (2003). Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA, 289, 2819-2826.
Foster NL (2003 Nov). Validating FDG-PET as a biomarker for frontotemporal dementia. Exp Neurol, 184 Suppl 1, S2-8.
Hong M, Shah GV, Adams KM, Turner RS, Foster NL (2002 Apr 23). Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Neurology, 58(8), 1285-7.
Kluin KJ, Gilman S, Foster NL, Sima AAF, DAmato C, Bruch LA, Bluemlein L, Little RJ, Johanns J (2001). Neuropathologic correlates of dysarthria in progressive supranuclear palsy. Arch Neurol, 58, 265-269.
Zubieta JK, Koeppe RA, Frey KA, Kilbourn MR, Mangner TJ, Foster NL, Kuhl DE (2001 Mar 15). Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. Synapse, 39(4), 275-87.
Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL (2001 Mar). Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol, 58(3), 411-6.
Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, Gonzales N, Lai E, Massman P (2001 Jul-Aug). Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord, 12(4), 295-300.
Connell CM, Shaw BA, Holmes SB, Foster NL (2001 Jul-Sep). Caregivers' attitudes toward their family members' participation in Alzheimer disease research: implications for recruitment and retention. Alzheimer Dis Assoc Disord, 15(3), 137-45.
Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE (2001 Sep). Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol, 50(3), 358-65.
Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AA, Keohane C, Nygaard TG, Fahn S, Mayeux R, Rowland LP, Wilhelmsen KC (2001 Nov). Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. 1994. Neurology, 57(10 Suppl 3), S39-45.
Foster NL, Minoshima S, Johanns J, Little R, Heumann ML, Kuhl DE, Gilman S (2000 May 9). PET measures of benzodiazepine receptors in progressive supranuclear palsy. Neurology, 54(9), 1768-73.
Foster NL, Gombosi E, Teboe C, Little RJ (2000 Jun 15-30). Balanced centralized and distributed database design in a clinical research environment. Stat Med, 19(11-12), 1531-44.
Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2000 Sep). Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol, 48(3), 391-5.
Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal LJ (2000 Nov 14). Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology, 55(9), 1271-8.
Whall AL, Black MEA, Yankou DJ, Groh CJ, Kupferschmid BJ, Foster NL, Little R (1999). Nurse aides' identification of onset and level of agitation in late stage dementia. Am J Alzheimers Dis Other Demen, 14, 202-206.
Foster NL (1999). Frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17): a clinician's guide. Neurologist, 5, 213-221.
Knopman DS, Berg JD, Thomas R, Grundman M, Thal LJ, Sano M, for Members of the Alzheimers Disease Cooperative Study Foster NL, et al (1999). Nursing home placement is related to dementia progression: experience from a clinical trial. Neurology, 52, 714-718.
Berent S, Giordani B, Foster NL, Minoshima S, Lajiness-ONeal R, Koeppe R, Kuhl DE (1999). Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J Psychiatr Res, 33, 7-16.
Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, Foster NL (1999). The effects of natural environments on agitation and aggression in late stage dementia. J Healthc Saf Compliance Infect Control, 3, 31-35.
Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR (1999 Mar 10). In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease. Neurology, 52(4), 691-9.
Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M, for the Dementia Trialists Collaboration Foster NL, et al (1998). Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. JAMA, 280, 1777-1782.
Minoshima S, Foster NL, Nishimura S, Kuhl DE (1998).
Glucose metabolic imaging for functional diagnosis of brain disorders: current status and prospects
. Rinsho Hoshasen. Japanese Journal of Clinical Radiology, 43, 1113-1121.
Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, Foster NL (1998).
Efecto del entorno natural sobre la agitacion y la agresion en pacientes con estado avanzado de demencia
. Metas de Enfermeria, 1(3), 12-18.
Mayeux R, Saunders AM, Shea S, Mirra S, Evans D, Roses AD, Hyman BT, Crain B, Tang M, Phelps CH, and the Alzheimers Disease Centers Consortium on APOE and Alzheimers Disease Foster NL, et al (1998). Utility of the APOE genotype in the diagnosis of Alzheimer's disease. N Engl J Med, 338, 506-511.
Fontana RJ, deVries TM, Woolf TF, Knapp MJ, Brown AS, Kaminsky LS, Tang BK, Foster NL, Brown RR, Watkins PB (1998 Sep). Caffeine based measures of CYP1A2 activity correlate with oral clearance of tacrine in patients with Alzheimer's disease. Br J Clin Pharmacol, 46(3), 221-8.
Bartok JA, Wilson CS, Giordani B, Keys BA, Persad CC, Foster NL, Berent S (1997). Varying patterns of verbal recall, recognition, and response bias with progression of Alzheimer's disease. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn, 4(4), 266-72.
Whall AL, Black ME, Groh CJ, Yankou DJ, Kupferschmid BJ, Foster NL (1997). The effects of natural environments on agitation and aggression in late stage dementia. Am J Alzheimers Dis Other Demen, 12, 216-220.
Morris JC, Ernesto C, Schafer K, Coats M, Leon S, Sano M, Thal LJ, Woodbury P, and the Alzheimers Disease Cooperative Study Foster NL, et al (1997). Clinical Dementia Rating training and reliability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology, 48, 1508-1510.
Sano M, Ernesto C, Thomas R, Klauber Mr, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ, for the Members of the Alzheimers Disease Cooperative Study Foster NL, et al (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med, 338, 1216-1222.
Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE (1997 May). Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med, 38(5), 797-802.
Foster NL, Wilhelmsen K, Sima AA, Jones MZ, DAmato CJ, Gilman S (1997 Jun). Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference Participants. Ann Neurol, 41(6), 706-15.
Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJ, Hariharan M, Foster NL (1997 Jul). Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease. Neurology, 49(1), 153-61.
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997 Jul). Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol, 42(1), 85-94.
Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J, Thal LJ, and Members of the Alzheimers Disease Cooperative Study Foster NL, et al (1996). Rationale and design of a multicenter study of selegiline and a-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer Dis Assoc Disord, 10, 132-140.
Knopman D, Schneider L, Davis K, Talwalker S, Smith F, Hoover T, Gracon S, and Tacrine Study Group Foster NL, et al (1996). Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology, 47, 166-177.
Sima AA, Defendini R, Keohane C, DAmato C, Foster NL, Parchi P, Gambetti P, Lynch T, Wilhelmsen KC (1996 Jun). The neuropathology of chromosome 17-linked dementia. Ann Neurol, 39(6), 734-43.
Fontana RJ, Turgeon DK, Woolf TF, Knapp MJ, Foster NL, Watkins PB (1996 Jun). The caffeine breath test does not identify patients susceptible to tacrine hepatotoxicity. Hepatology, 23(6), 1429-35.
Fisher NJ, Rourke BP, Bieliauskas L, Giordani B, Berent S, Foster NL (1996 Jun). Neuropsychological subgroups of patients with Alzheimer's disease. J Clin Exp Neuropsychol, 18(3), 349-70.
Butter CM, Trobe JD, Foster NL, Berent S (1996 Jul). Visual-spatial deficits expalin visual symptoms in Alzheimer's disease. Am J Ophthalmol, 122(1), 97-105.
Cochran EJ, Bennett DA, Cervenakova L, Kenney K, Bernard B, Foster NL, Benson DF, Goldfarb LG, Brown P (1996 Sep). Familial Creutzfeldt-Jakob disease with a five-repeat octapeptide insert mutation. Neurology, 47(3), 727-33.
Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA (1996 Sep). In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol, 40(3), 399-410.
Murman DL, Foster NL, Kilgore SP, McDonagh CA, Fink JK (1996 Sep-Oct). Apolipoprotein E and Alzheimer's disease: strength of association is related to age at onset. Dementia, 7(5), 251-5.
Foster NL, Petersen RC, Gracon SI, Lewis K (1996 Sep-Oct). An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group. Dementia, 7(5), 260-6.
McDaniel KD, Edland SD, Heyman A, and the CERAD Clinical Investigators Foster NL, et al (1995). Relationship between level of insight and severity of dementia in Alzheimer disease. Alzheimer Dis Assoc Disord, 9, 101-104.
Meyer M, Koeppe RA, Frey KA, Foster NL, Kuhl DE (1995 Mar). Positron emission tomography measures of benzodiazepine binding in Alzheimer's disease. Arch Neurol, 52(3), 314-7.
Alexander NB, Mollo JM, Giordani B, Ashton-Miller JA, Schultz AB, Grunawalt JA, Foster NL (1995 May). Maintenance of balance, gait patterns, and obstacle clearance in Alzheimer's disease. Neurology, 45(5), 908-14.
Minoshima S, Frey KA, Foster NL, Kuhl DE (1995 Jul-Aug). Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr, 19(4), 541-7.
Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE (1995 Jul). A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med, 36(7), 1238-48.
Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE (1995 Dec). PET of peripheral benzodiazepine binding sites in the microgliosis of Alzheimer's disease. J Nucl Med, 36(12), 2207-10.
Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI, and Tacrine Study Group Foster NL, et al (1994). A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA, 271, 985-991.
Lynch T, Sano M, Marder KS, Bell KL, Foster NL, Defendini RF, Sima AA, Keohane C, Nygaard TG, Fahn S, et al (1994 Oct). Clinical characteristics of a family with chromosome 17-linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology, 44(10), 1878-84.
Kluin KJ, Foster NL, Berent S, Gilman S (1993 Mar). Perceptual analysis of speech disorders in progressive supranuclear palsy. Neurology, 43(3 Pt 1), 563-6.
Shope JT, Holmes SB, Sharpe PA, Goodman C, Izenson S, Gilman S, Foster NL (1993 Aug). Services for persons with dementia and their families: a survey of information and referral agencies in Michigan. Gerontologist, 33(4), 529-33.
Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadowsky CH, Dolan-Ureno J, and the Tacrine Study Group Foster NL, et al (1992). A controlled trial of tacrine in Alzheimer's disease. JAMA, 268, 2523-2529.
Goldman R, Axelrod BN, Giordani B, Foster NL, Berent S (1992). Longitudinal sensitivity of the Fuld cholinergic profile to Alzheimer's disease. J Clin Exp Neuropsychol, 14, 566-574.
Boivin MJ, Giordani B, Berent S, Amato DA, Lehtinen S, Koeppe RA, Buchtel HA, Foster NL, Kuhl DE (1992 Jun). Verbal fluency and positron emission tomographic mapping of regional cerebral glucose metabolism. Cortex, 28(2), 231-9.
Foster NL, Gilman S, Berent S, Sima AA, DAmato C, Koeppe RA, Hicks SP (1992 Aug). Progressive subcortical gliosis and progressive supranuclear palsy can have similar clinical and PET abnormalities. J Neurol Neurosurg Psychiatry, 55(8), 707-13.
Bromberg MB, Aldrich MS, Foster NL, Berent S (1990). The Kluver-Bucy syndrome preceding ventricular enlargement in normal pressure hydrocephalus. Dementia, 1, 169-174.
Mountz JM, Modell JG, Foster NL, DuPree ES, Ackermann RJ, Petry NA, Bluemlein LE, Kuhl DE (1990 Jan). Prognostication of recovery following stroke using the comparison of CT and technetium-99m HM-PAO SPECT. J Nucl Med, 31(1), 61-6.
Giordani B, Boivin MJ, Hall AL, Foster NL, Lehtinen SJ, Bluemlein LA, Berent S (1990 Dec). The utility and generality of Mini-Mental State Examination scores in Alzheimer's disease. Neurology, 40(12), 1894-6.
Foster NL, Aldrich MS, Bluemlein L, White RF, Berent S (1989 Feb). Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology, 39(2 Pt 1), 257-61.
Grady CL, Grimes AM, Patronas N, Sunderland T, Foster NL, Rapoport SI (1989 Mar). Divided attention, as measured by dichotic speech performance, in dementia of the Alzheimer type. Arch Neurol, 46(3), 317-20.
Aldrich MS, Foster NL, White RF, Bluemlein L, Prokopowicz G (1989 Jun). Sleep abnormalities in progressive supranuclear palsy. Ann Neurol, 25(6), 577-81.
Sheridan PH, Sato S, Foster NL, Bruno G, Cox C, Fedio P, Chase TN (1988). Relation of EEG alpha background to parietal lobe function in Alzheimer's disease as measured by positron emission tomography and psychometry. Neurology, 38, 747-750.
Berginer VM, Foster NL, Sadowsky M, Townsend JA 3rd, Siegel GJ, Salen G (1988 Mar). Psychiatric disorders in patients with cerebrotendinous xanthomatosis. Am J Psychiatry, 145(3), 354-7.
Foster NL, Mountz JM, Bluelein LA, Ackermann RJ, Petry NA, Kuhl DE (1988 Jun). Blood flow imaging of a posterior circulation stroke. Use of technetium Tc 99m hexamethylpropyleneamine oxime and single photon emission computed tomography. Arch Neurol, 45(6), 687-90.
Foster NL, Gilman S, Berent S, Morin EM, Brown MB, Koeppe RA (1988 Sep). Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann Neurol, 24(3), 399-406.
Mountz JM, Foster NL, Ackermann RJ, Bluemlein L, Petry NA, Kuhl DE (1988 Oct). SPECT imaging of moyamoya disease using 99mTc-HM-PAO. Comparison with computed tomography findings. J Comput Tomogr, 12(4), 247-50.
Tamminga CA, Foster NL, Fedio P, Bird ED, Chase TN (1987 Jan). Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology, 37(1), 161-5.
Foster NL, VanDerSpek AF, Aldrich MS, Berent S, Hichwa RH, Sackellares JC, Gilman S, Agranoff BW (1987 Aug). The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease as measured using positron emission tomography. J Cereb Blood Flow Metab, 7(4), 415-20.
Mohr E, Burns G, Foster NL, Gillespie M, Cox C, Hare TA, Tamminga C, Fedio P, Chase TN (1986). GABA-agonist therapy of Alzheimer's disease. Clin Neuropharmacol, 9, 257-263.
Irving CS, Marks L, Klein PD, Foster NL, Gadde PL, Chase TN, Samuel D (1986). New evidence for taurine biosynthesis in man obtained from 1802 inhalation studies. Life Sci, 38, 491-495.
Foster NL, Tamminga CA, ODonohue TL, Tanimoto K, Bird ED, Chase TN (1986 Jan 2). Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease. Neurosci Lett, 63(1), 71-5.
Foster NL, Chase TN, Patronas NJ, Gillespie MM, Fedio P (1986 Feb). Cerebral mapping of apraxia in Alzheimer's disease by positron emission tomography. Ann Neurol, 19(2), 139-43.
Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL (1986 Apr). Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry, 43(4), 398-402.
Martin A, Brouwers P, Lalonde F, Cox C, Teleska P, Fedio P, Foster NL, Chase TN (1986 Oct). Towards a behavioral typology of Alzheimer's patients. J Clin Exp Neuropsychol, 8(5), 594-610.
Newman RP, LeWitt PA, Shults C, Bruno G, Foster NL, Chase TN, Calne DB (1985). Dystonia: treatment with bromocriptine. Clin Neuropharmacol, 8(4), 328-33.
Grimes AM, Grady CL, Foster NL, Sunderland T, Patronas NJ (1985 Mar). Central auditory function in Alzheimer's disease. Neurology, 35(3), 352-8.
Hurst JH, LeWitt PA, Burns RS, Foster NL, Lovenberg W (1985 Apr). CSF dopamine-beta-hydroxylase activity in Parkinson's disease. Neurology, 35(4), 565-8.
Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Di Chiro G (1984). Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann Neurol, 15 Suppl, S170-4.
Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Kessler R, Di Chiro G (1984). Gilles de la tourette syndrome: studies with the fluorine-18-labeled fluorodeoxyglucose positron emission tomographic method. Ann Neurol, 15 Suppl, S175.
Karson CN, Burns RS, LeWitt PA, Foster NL, Newman RP (1984 May). Blink rates and disorders of movement. Neurology, 34(5), 677-8.
Foster NL, Newman RP, LeWitt PA, Gillespie MM, Chase TN (1984 Oct). Treatment of resting tremor by beta-adrenergic blockade. Am Heart J, 108(4 Pt 2), 1173-7.
Foster NL, Newman RP, LeWitt PA, Gillespie MM, Larsen TA, Chase TN (1984 Oct). Peripheral beta-adrenergic blockade treatment of parkinsonian tremor. Ann Neurol, 16(4), 505-8.
Chase TN, Fedio P, Foster NL, Brooks R, Di Chiro G, Mansi L (1984 Dec). Wechsler Adult Intelligence Scale performance. Cortical localization by fluorodeoxyglucose F 18-positron emission tomography. Arch Neurol, 41(12), 1244-7.
Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, Di Chiro G (1984 Dec). Cortical abnormalities in Alzheimer's disease. Ann Neurol, 16(6), 649-54.
LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster NL, Dambrosia J, Calne DB (1983). Comparison of pergolide and bromocriptine therapy in parkinsonism. Neurology, 33(8), 1009-1014.
Foster NL, Chase TN, Denaro A, Hare TA, Tamminga CA (1983 May). THIP treatment of Huntington's disease. Neurology, 33(5), 637-9.
Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, Di Chiro G (1983 Aug). Alzheimer's disease: focal cortical changes shown by positron emission tomography. Neurology, 33(8), 961-5.
Chase TN, Brooks RA, DeLaPaz RL, DiChiro G, Durso R, Fedio P, Foster NL, Kessler RM, Kornblith PL, Kufta CV, Manning RG, Newmark ME, Patronas NJ, Porter R, Sato S, Smith BH, and Theodore WH (1982). Positron emission tomographic studies of epilepsy, brain tumors, and Alzheimer's disease. Psychopharmacol Bull, 18(3), 3-6.
Foster NL (1980 Jul). Progressive supranuclear palsy and hyperkalemic periodic paralysis. Arch Neurol, 37(7), 461-2.
Foster NL, Wing SD, Bray PF (1980 Dec). Metrizamide ventriculography in syringomyelia. Neurology, 30(12), 1323-6.
Foster NL, Campbell B (1976). The effect of diphenylhydantoin on the microbial assay of serum folate. Clin Biochem, 9, 22-23.

Review

Book Chapter

Foster NL (). Neuroimaging. In Weiner MF, Lipton AM (Eds.), Clinical Manual of Alzheimer Disease and Other Dementias (pp. 89-126). Washington DC: American Psychiatric Publishing, Inc.
Foster NL (). Molecular Imaging in Neuropsychiatry. In Coffey CE, Cummings JL (Eds.), The American Psychiatric Publishing Textbook of Geriatric Neuropsychiatry (3rd Ed, pp. 177-209). Washington: American Psychiatric Publishing, Inc.
Provenzale J, Foster NL, King RD (2010; In Press). Alzheimer Disease. In Osborn AG, Salzman KL, Barkovich J, et al (Eds.), Diagnostic Imaging: Brain (Second Edition, pp. 74-77). Amirsys/Lippincott Wililams and Wilkins.
Foster NL (2009). Neuroimaging. In Weiner MF, Lipton AM (Eds.), The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias (pp. 105-136). Washington: American Psychiatric Publishing, Inc.
Foster NL (2008). Strategies for using molecular neuroimaging in dementia. In Duyckaerts C, Litvan I (Eds.), Dementias: Handbook of Clinical Neurology (89, pp. 87-95). Elsevier: Edinburgh; New York. PMID: 18631733.
Foster NL (2006). The Clinical Issues. In Herholz K, Perani D, Morris C (Eds.), The Dementias: Early Diagnosis and Evaluation (pp. 1-26). New York: Taylor and Francis.
Foster NL, Koeppe RE, Giordani BJ, Nichols TE, Lieberman AP (2005). Variations of the phenotype in frontotemporal dementias. In Cummings J, Hardy J, Poncet M, Christen Y (Eds.), Genotype - Proteotype - Phenotype Relationships in Neurodegenerative Diseases (2005, pp. 139-52). Berlin: Springer-Verlag.
Foster NL (2004). Neuroimaging techniques: CT, MRI, SPECT, PET. In Richter RW, Richter BZ (Eds.), Current Clinical Neurology, Alzheimer's Disease: A Physician's Guide to Practical Management (pp. 89-102). Totowa NJ: Humana Press Inc.
Foster NL (2003). Neuropsychiatry of dementing disorders. In Fogel BS, Schiffer RB, Rao SM (Eds.), Neuropsychiatry (2nd Ed, pp. 1034-70). New York: Lippincott Williams and Wilkins.
Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, Foster NL, Schneider LS, Sano M, Whitehouse P, Tariot P, Mellow AM, Auchus AP, Grundman M, Thomas RG, Schafer K, Thal L J, and Members of the Alzheimers Disease Cooperative Study (2002). Treatment of agitation in Alzheimer's disease: an investigation of haloperidol, trazodone and behavior management techniques. In Vellas B, Fitten J, Winblad B, Feldman H, Grundman M, Giacobini E, Kurz A (Eds.), Research and Practice in Alzheimer's Disease (6, pp. 232-236). Paris: Serdi.
Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL (2002). Synopsis of: mild cognitive impairments predict dementia in non-demented elderly with memory loss. In Vellas B, Fitten J, Winblad B, Feldman H, Grundman M, Giacobini E, Kurz A (Eds.), Research and Practice in Alzheimer's Disease (6, pp. 43-47). Paris: Serdi.
Heidebrink JL, Foster NL (1999). Dementia. In Shah SM, Kelly KM (Eds.), Emergency Neurology: Principles and Practice (pp. 312-325). New York: Cambridge University Press.
Foster NL, Minoshima S, Kuhl DE (1999). Brain imaging in Alzheimer disease. In Terry RD, Katzman R, Bick KL, Sisodia SS (Eds.), Alzheimer Disease (2nd Ed, pp. 67-93). Philadelphia: Lippincott Williams and Wilkins.
Farlow MR, Brashear A, Hui S, Schneider L, Unverzagt F, Tacrine Study Group Foster NL, et al (1995). The effects of tacrine in patients with mild versus moderate stage Alzheimer's disease. In Iqbal K, Mortimer JA, Winblad B, Wisniewski HM (Eds.), Research Advances in Alzheimer's Disease and Related Disorders (pp. 282-292). New York: John Wiley and Sons Ltd.
Foster NL (1994). PET imaging. In Terry RD, Katzman R, Bick KL (Eds.), Alzheimer Disease (pp. 87-103). New York: Raven Press.
Mayeux RP, Foster NL, Rossor M, Whitehouse PJ (1993). Clinical evaluation of dementia. In Whitehouse PJ (Ed.), Dementia (pp. 92-129). Philadelphia: F.A. Davis Co.
Foster NL (1990). Dementia in movement disorders. In Martin WRW (Ed.), Functional Imaging in Movement Disorders (pp. 215-232). Ann Arbor: CRC Press.
Foster NL (1989). Brain imaging as a useful tool in the diagnosis of dementia. In Altman HJ, Altman BN (Eds.), Alzheimer's and Parkinson's Diseases. Recent Advances in Research and Clinical Management (pp. 19-38). New York: Plenum Press.
Foster NL (1987). Age-related changes in the human nervous system. In Mueller HG, Geoffrey VC (Eds.), Communication Disorders in Aging: Assessment and Management (pp. 3-35). Washington, DC: Gallaudet University Press.
Foster NL, Chase TN (1985). Huntington's disease. In Johnson RT (Ed.), Current Therapy in Neurology Disease (pp. 244-247). Philadelphia: B.C. Decker, Inc.
Chase TN, Brooks RA, DiChiro G, Fedio P, Foster NL, Kessler RA, Mansi L, Manning RG, Patronas NJ (1985). Focal cortical abnormalities in Alzheimer's disease. In Greitz T, Ingvar DH, Widen L (Eds.), The Metabolism of the Human Brain Studied with Positron Emission Tomography (pp. 433-440). New York: Raven Press.
Chase TN, Foster NL (1984). Alterations in local cortical glucose metabolism in Alzheimer's disease. In Lassen NA, Hossmarin KA, Reivich M, Agnoli A, Cahn J (Eds.), Drugs and Diseases (1, pp. 175-180). London: John Libbey Eurotex Ltd.
Chase TN, Foster NL, Fedio P, Mansi L, Brooks R, Kessler R, Di Chiro G (1984). Cognitive and cerebral metabolic function in early and advanced Alzheimer's disease. In Monogr Neural Sci (11, pp. 176-9). Switzerland.
Chase TN, Foster NL, Fedio P, DiChiro G, Patronas NJ (1983). Alzheimer's disease: Local cerebral metabolism studies using the 18F-fluorodeoxyglucose-positron emission tomography technique. In Samuel D, Ageri S, Gershon S, Grimm VE, Toffano G (Eds.), Aging of the Brain (pp. 43-154). New York: Raven Press.

Conference Proceedings

Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, et al (2009). A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement, 5(2), 85-92.
Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Fillit H, Foster N (5/1/2008). A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. Alzheimers Dement, 4(3), 156-63.
Fletcher PT, Powell S, Foster NL, Joshi SC (2007). Quantifying metabolic asymmetry modulo structure in Alzheimer's disease. In Karssemeijer N, Lelieveldt B (Eds.), Information Processing in Medical Imaging (Proceedings, 20th International Conference, IPMI 2007, Kerkrade, The Netherlands, July 2-6, 2007), Germany: Springer-Verlag, 20, 446-57.
Tasdizen T, Awate SP, Whitaker RT, Foster NL (2005). MRI tissue classification with neighborhood statistics: A nonparametric, entropy-minimizing approach. In Duncan JS, Gerig G (Eds.), Medical Image Computing and Computer-Assisted Intervention – MICCAI 2005 (8th International Conference, Palm Springs, CA, USA, October 2005, Proceedings), New York: Springer, 8(Pt 2), 517-25.
Foster NL, Bozoki A, Minoshima S, Kuhl DE, Giordani B, Berent S (2002). Isolated memory impairment: Clues from imaging and follow-up studies. In Binetti G, Alberici A, Ghidoni R, Zanetti O (Eds.), The Shadow Line from Normal Aging to Dementia: Clinical, Genetic and Ethical Aspects (Proceedings of the Meeting held in Brescia the 20-22 of September 2001), Brescia: IRCCS Centro San Giovanni di Dio FBF, 27-35.
Minoshima S, Foster NL, Cross DJ, Kuhl DE (2000). PET investigations of dementia. In Tamaki N, Tsukamoto E, Kuge Y, Katoh C, Morita K (Eds.), Positron Emission Tomography in the Millennium (Proceedings of the International PET Symposium held in Hokkaido, Japan 24-26th September 1999), Amsterdam: Elsevier Science, 17-22.
Minoshima S, Frey KA, Foster NL, Kuhl DE (1997). Diagnostic applications of PET in dementia. In Ishii Y, Yonekura Y, Fujibayashi Y, Sadato N (Eds.), Recent Advances in Biomedical Imaging (Proceedings of the International Workshop on Biomedical Imaging: MR and PET/SPECT, Fukui, Japan, 28-30 August, 1996), New York: Elsevier Science, 103-107.

Editorial

Foster NL, Jagust WJ, Fox NC (2013 Jan-Mar). A peek behind the curtain: amyloid imaging, referrals, and specialist memory evaluations. Patient Exp J, 27(1), 1-3.
Foster NL (2007 Aug). A new framework for the diagnosis of Alzheimer's disease. Lancet Neurol, 6(8), 667-9.
Foster NL (2003). New opportunities to study real-world patient management. Scand J Gastroenterol, 38, 341-342.
Barbas N, Foster NL (2001). Social and ethical issues in the care of patients with dementia. J Geriatr Psychiatry Neurol, 14, 167.
Foster NL, Hickenbottom SL (1999 Jul). When do strokes cause dementia? Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch Neurol, 56(7), 778-9.

Letter

Foster NL (). Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Appropriate Drug Treatment Depends on Cause of Dementia [Invited Rapid Response Letter]. Retrieved March 21, 2008 from www.annals.org [Letter to the editor]. Ann Intern Med.
Porter AB, Healy L, Foster NL, Josephs KA (2007). Compulsive urination as a presenting symptom of frontotemporal dementia [Letter to the editor]. Eur J Neurol, 14(8), e16-7.
Foster NL, Hong M, Shah GV, Adams KM, Turner RS (2002). Reply to "Spontaneous intracranial hypotension causing reversible frontotemporal dementia" [Letter to the editor]. Neurology, 59, 787.
Kluin KJ, Gilman S, Foster NL, DAmato C, Bluemlein L, Little RJ, Sima AAF, Bruch LA, Johanns J (2001). Reply to: "Neuropathologic correlates of dysarthria in progressive supranuclear palsy" [Letter to the editor]. Arch Neurol, 58, 1500.
Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2001). Reply to: "Central acetylcholinesterase inhibition in Alzheimer patients" [Letter to the editor]. Ann Neurol, 49, 416-417.
Foster NL, Fitzgerald J, Remick DGJ (1996).
Letter to the Editor
[Letter to the editor]. Gerontology News, 2.
Gilman S, Foster NL (1996 Feb). "The Alzheimerization of aging": a response [Letter to the editor]. Gerontologist, 36(1), 9-10.
Minoshima S, Foster NL, Kuhl DE (1994 Sep 24). Posterior cingulate cortex in Alzheimer's disease [Letter to the editor]. Lancet, 344(8926), 895.
Tamminga CA, Foster NL, Chase TN (1985 Nov 14). Reduced brain somatostatin levels in Alzheimer's disease [Letter to the editor]. N Engl J Med, 313(20), 1294-5.
Foster NL, Chase TN (1983 Feb). Diffuse involvement in progressive aphasia [Letter to the editor]. Ann Neurol, 13(2), 224-5.
Chase TN, Foster NL, Mansi L (1983 Jul 23). Alzheimer's disease and the parietal lobe [Letter to the editor]. Lancet, 2(8343), 225.

Abstract

Gerard Bischof, Peter Bartenstein, Henryk Barthel, Bart Van Berckel, Vincent Dore, Thilo Van Eimeren, Norman Foster, Jochen Hammes, Adriaan Lammertsma, Satoshi Minoshima, Christopher Rowe, Osama Sabri, John Seibyl, Koen Van Laere, Rik Vandenberghe, Victor Villemagne, Igor Yakushev, amp Alexander Drzezga (). Comparing Amyloid PET Tracers and Interpretation Strategies: First Results from the CAPTAINs Study [Abstract]. J Nucl Med, 2018(59), 485.
Smiley S, Nielsen J, Gurgel R, Zielinski B, Wright B, Wang A, Auduong P, Foster NF, Giraud-Carrier C, Anderson J (). Validation of quantitative regional atrophy dementia classification in a large clinical MRI sample [Abstract]. Organization for Human Brain Mapping Annual Meeting.
Gurgel R, Audoung P, Anderson J, Foster NL, et al (). An evaluation of the effect of cognitive impairment on auditory cortical brain [Abstract]. Association for Research in Otolaryngology, 37, 293-294.
Ganz M, Tawah A, Chitnis A, Pharm M, Silies H, Schauble B, Foster NL (). Expected Impact of Amyloid B Positron Emission Tomography on Diagnostic and Treatment Decisions for Suspected Alzheimer's Disease Patients. Also shared as a CME activity [Abstract]. Alzheimer's and Dementia, 10(4), 556-557.
Manley N, Foster NL, Supiano M (). Posterior Cortical Atrophy [Abstract]. Journal of the American Geriatric Society, 62(1).
Chew J, Pomykala KL, Po L, Foster NL, Hoffman JM, Dennett K, Zamrini E, Czernin J, Phelps ME, Silverman DH (). Obtaining brain PET data is associated with more AD-specific drug prescription and improved clinical outcomes for subjects with cerebrometabolic evidence of AD [Abstract]. J Nucl Med MEETING ABSTRACTS, 54, 1804.
Hammers D, Jolley C, Card S, Duff K, Chelune G, Stearn M, Foster NL (). Converting Montreal Cognitive Assessment to Mini-Mental Status Examination Scores and Vice Versa in a Clinical Sample [Abstract]. Annual meeting of the International Neuropsychological Society (Waikoloa, HI).
Duff K, Foster NL, Dennett K, et al (). Amyloid deposition and cognition in older adults: The effects of premorbid intellect [Abstract]. 7th Human Amyloid Imaging Meeting, Miami 2013, Schedule and Abstract Book, Online, 23.
Duff K, Foster NL, Hoffman J (). Practice effects and amyloid deposition: A method for enriching samples in clinical trials [Abstract]. 7th Human Amyloid Imaging Meeting, Miami 2013, Schedule and Abstract Book, Online, 54.
Hammers D, Duff K, Dennett K, Hoffman J, Chelune G, Thurfjell L, Wang A, Morton K, Zollinger L, Foster NL (). Flutemetamol Uptake and Cognitive Performance in Non-Demented Community-Dwelling Elders [Published abstract, 2012 AAN Meeting, Emerging Science] [Abstract]. Neurology, 79(11), e88-9.
Foster NL, Wang AY, King RD, Zamrini E, Yachnis A, Chin S (). Discrepant FDG-PET and Neuropathological Findings in Patients Scanned to Distinguish Frontotemporal Dementia from Alzheimer's Disease Dementia [#P163, presented at the 8th International Conference on Frontotemporal Dementias (Manchester, UK)] [Abstract]. Dement Geriatr Cogn Disord, 34(Suppl 1), 153-4.
Ghetti B, Murrell J, Koeppe R, Gilman S, Fink J, Miravalle L, Albin R, Vidal R, Foster NL (). Follow-up of the first American report of familial Alzheimer's disease [Published abstract P4-091. Alzheimer’s Association International Conference 2012] [Abstract]. Alzheimers Dement, 8(4 Suppl), P665.
Protas H, Chen K, Reschke C, Roontiva A, Lee W, Nishimura M, Ayutyanont N, Liu X, Thiyyagura P, Parks S, Koeppe R, Jagust W, Foster NL, Weiner M, Fleisher A, Reiman E (). Capitalizing on complementary FDG PET and florbetapir PET data sets to distinguish between early and late mild cognitive impairment using multi-modal partial least squares [Published abstract IC-P-024 and P2-217. Alzheimer’s Association International Conference 2012] [Abstract]. Alzheimers Dement, 8(4 Suppl), P20 and P334.
Silverman D, Chew J, Geist C, Pomykala K, Lu P, Foster NL, Hoffman J, Dennett K, Czernin J, Phelps M (). Prescription of Alzheimer's-specific drugs and long-term preservation of language function are positively associated with early release of regional cerebral metabolic data in a multi-center prospective randomized trial [Published abstract O4-09-03. Alzheimer’s Association International Conference 2012] [Abstract]. Alzheimers Dement, 8(4 Suppl), P631-2.
Zamrini E, Andersen T, Foster NL (). Proactive dementia care: First-year findings [Published abstract #P3-411. Alzheimer’s Association International Conference 2012] [Abstract]. Alzheimers Dement, 8(4 Suppl), P599-600.
Foster NL, King R, Wang A Y, Landau S, Jagust W, Chen K, Reiman E (). Discrepant diagnostic classification with AV45-PET and FDG-PET of clinically diagnosed Alzheimer's patients in the Alzheimer's Disease Neuroimaging Initiative [Published abstract #P1-007. Alzheimer’s Association International Conference 2012] [Abstract]. Alzheimers Dement, 8(4 Suppl), P109-10.
Chew J, Geist C, Pomykala K, Foster NL, Hoffman J, Dennett K, Zamrini E, Czernin J, Phelps M, Silverman D (). Prescription pattern of Alzheimer-specific drugs is positively associated with immediate release of brain PET scan data in the Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID) trial [Published Abstract. SNM 2012 Meeting] [Abstract]. J Nucl Med, 53(Suppl 1), 1958.
Zollinger L, Duff K, Butterfield R, Christian P, Thurfjell L, Foster NL, Morton K, Hoffman J (). Evaluating the correlation of 18F-flutemetamol uptake with measures of memory function in non-demented seniors [Published Abstract. SNM 2012 Meeting] [Abstract]. J Nucl Med, 53(Suppl 1), 1970.
Zamrini E, Mandal P, Andersen T, Simpson C, Wang A, Greene T, Ying J, King R, Foster NL (). Proactive Dementia Care: A Five-Year Experience in Dementia Caregiver Counseling [Published abstract #P07.156, 2012 AAN Meeting] [Abstract]. Neurology, 78(Meeting abstracts 1), P07.156.
Minshew L, Foster NL, King RD, Wang A Chin S (). Frequency of Frontal Hypometabolism in Autopsy Confirmed AD Subjects [Published abstract #S14.006, 2012 AAN Meeting] [Abstract]. Neurology, 78(Meeting abstracts 1), S14:006.
Foster NL, King R, Wang A, Landau S, Jagust W, Chen K, Reiman E (). Diagnostic Classification with Amyloid PET and FDG-PET among Clinically Diagnosed Alzheimer’s Disease Patients in the Alzheimer’s Disease Neuroimaging Initiative [Abstract]. Human Amyloid Imaging, Miami 2012, Schedule and Abstract Book, p. 63, Online.
Duff K, Foster NL, Hoffman J, Dennett K, Thurfjell L, Wang A Y, Zollinger L, Morton K, Gallagher K (). Regional Brain Differences in Flutemetamol Uptake and Practice Effects [Abstract]. Human Amyloid Imaging, Miami 2012, Schedule and Abstract Book, p. 62, Online.
Duff K, Hoffman J, Foster NL, Dennett K, Thurfjell L, Wang A, Morton K, Zollinger L, Gallagher K (). Flutemetamol is related to Practice Effects on Cognitive Testing [Abstract]. Human Amyloid Imaging, Miami 2012, Schedule and Abstract Book, p.61. Online.
Protas H, Chen K, Roontiva A, Ayutyanont N, Liu X, Parks S, Nishimura M, Reschke C, Jagust W, Foster NL, Weiner M, Fleisher A, Reiman E (). Standard and Novel PET Measurements of Amyloid Burden, Relationships to Clinical Severity, and Relationships to an AD-Related Hypometabolic Convergence Index in Early MCI [Abstract]. Human Amyloid Imaging, Miami 2012, Schedule and Abstract Book, p. 53, Online.
Ayutyanont N, Chen K, Roontiva A, Fleisher A, Langbaum J, Reschke C, Lee W, Liu X, Bandy C, Alexander G, Foster NL, Harvey D, Weiner M, Koeppe R, Jagust W, Reiman E, The Alzheimers Disease Neuroimaging Initiative (). Use of an FDG-PET derived hypometabolic convergence index enrichment strategy to reduce sample sizes in Alzheimer's disease clinical trials: findings from the Alzheimer's Disease Neuroimaging Initiative (ADNI) [Published Abstract. Alzheimer’s Association International Conference on Alzheimer’s Disease 2011, #P2-190 / #IC-P-084] [Abstract]. Alzheimers Dement, 7(4 Suppl), S373-4, S43.
King RD, Bingham C, Wang AY, Hu N, Foster NL (). Demographic and Cognitive Profiles of Alzheimer's Disease Subjects Demonstrating a Pattern of Cerebral Metabolism Suggesting Frontotemporal Dementia [American Academy of Neurology Annual Meeting 2011, Poster #PD2.005] [Abstract]. Neurology, 76(Suppl 4), A190.
Foster NL, Dennett K, Zamrini E, King RD, Carlson PJ, Wang AY, Silverman D, Hoffman J (). FDG-PET in Evaluating Mild Cognitive Probelms in a Clinical Population [American Academy of Neurology Annual Meeting 2011, Poster #SC02.001] [Abstract]. Neurology, 76(Suppl 4), A660.
Duff K, Chelune GJ, Wang AY, Card S, Franchow E, Zamrini E, Foster NL (). FDG-PET correlates of memory in a sample of patients with dementia [National Academy of Neuropsychology Annual Conference 2010, Poster #A-1] [Abstract]. Archives of Clinical Neuropsychology, 25(6), 480.
Chelune GJ, Duff K, Wang A Y, Franchow E, Card S, Zamrini E, Foster NL (). 18FDG-PET correlates of semantic (SF) and letter fluency (LF) in patients with dementia [National Academy of Neuropsychology Annual Conference 2010, Poster #A-2] [Abstract]. Archives of Clinical Neuropsychology, 25(6), 480.
Chen K, Ayutyanont N, Langbaum J, Fleisher A, Reschke C, Lee W, Liu X, Alexander GE, Bandy D, Yu M, Foster NL, Weiner MW, Thompson PM, Koeppe RA, Jagust WJ, Reiman EM, Alzheimers Disease Neuroimaging Initiative (). Use of an Alzheimer's Disease-Related Hypometabolic Convergence Index to Predict Progression from Mild Cognitive Impairment to Alzheimer's Dementia [Alzheimer’s Association International Conference on Alzheimer’s Disease 2010, #P1-416] [Abstract]. Alzheimer’s Dement, 6(4 Suppl 1), S296.
Fletcher PT, Kumar A, Wang AY, Jagust WJ, Chen K, Reiman EM, Weiner MW, Foster NL, Alzheimers Disease Neuroimaging Initiative (). Regression-to-pons normalization of FDG-PET improves discrimination of Alzheimer's disease from healthy aging [Alzheimer’s Association International Conference on Alzheimer’s Disease 2010, #IC-P-016] [Abstract]. Alzheimer’s Dement, 6(4 Suppl 1), S11-12.
Landau SM, Harvey D, Reiman EM, Foster NL, Aisen PS, Trojanowski JQ, Shaw L, Jack CR, Petersen RC, Weiner MW, Jagust WJ (). Biomarker predictors of cognitive decline in healthy older participants in the Alzheimer's Disease Neuroimaging Initiative [Alzheimer’s Association International Conference on Alzheimer’s Disease 2010, #O3-03-08] [Abstract]. Alzheimer’s Dement, 6(4 Suppl 1), S131.
Foster NL, Wang AY, Fletcher PT, Joshi S, Minoshima S, Jagust WJ, Chen K, Reiman EM, Weiner MW, Alzheimers Disease Neuroimaging Initiative (). Topographic extent of cerebral hypometabolism predicts time of conversion from aMCI to AD: Data from the Alzheimer’s Disease Neuroimaging Initiative [Alzheimer’s Association International Conference on Alzheimer’s Disease 2010, #P1-421] [Abstract]. Alzheimer's Dement, 6(4 Suppl 1), S298.
Landau SM, Harvey D, Madison C, Foster NL, Reiman EM, Shaw LM, Trojanowski JQ, Petersen RC, Weiner MW, Jagust WJ (2009). Comparing Predictors of Conversion: Data from the Alzheimer’s Disease Neuroimaging Initiative (Oral Presentation #O3-01-01) [Abstract]. Alzheimer's & Dementia, 5(4 Suppl), P125.
Landau SM, Madison C, Cheung C, Foster N, Reiman E, Koeppe R, Weiner M, Jagust W (1/1/2008). Optimizing FDG PET Measurements for Prediction of Cognitive Decline: Findings from the Alzheimer’s Disease Neuroimaging Initiative [Abstract]. Neuroscience, 47.3(V23).
Chen K, Reschke C, Lee W, Bandy D, Foster NL, Weiner MW, Koeppe, RA, Jagust WJ, Reiman EM (7/1/2008). The pattern of cerebral hypometabolism in amnestic mild cognitive impairment and its relationship to subsequent conversion to probable Alzheimer’s disease: Preliminary findings from the Alzheimer’s Disease Neuroimaging Initiative [Abstract]. Alzheimer's & Dementia, 4(2), T42.
Chen K, Lee W, Liu X, Alexander GE, Bandy D, Reschke C, Foster NL, Weiner MW, Koeppe, RA, Jagust WJ, Reiman EM (7/1/2008). The consistency of hypometabolic brain voxels in probable Alzheimer’s disease and amnestic mild cognitive impairment patients from the Alzheimer’s Disease Neuroimaging Initiative [Abstract]. Alzheimer's & Dementia, 4(2), T318.
Landau SM, Madison C, Wu D, Cheung C, Foster N, Reiman E, Koeppe R, Weiner M, Jagust WJ (7/1/2008). Pinpointing Change In Alzheimer’s Disease: Longitudinal FDG-PET Analyses From the Alzheimer’s Disease Neuroimaging Initiative [Abstract]. Alzheimer's & Dementia, 4(2), T291.
Pinpointing Change In Alzheimers Disease Longitudinal FDG-PET Analyses From The Alzheimers Disease Neuroimaging Initiative (7/1/2008). Landau SM, Madison C, Wu D, Cheung C, Foster NL, Reiman E, Koeppe R, Weiner M, Jagust WJ [Abstract]. Alzheimer's & Dementia, 4(2), T291.
Meta-Analysis ROIs And Minimal Deformation Templates Improve FDG-PET As a Candidate Biomarker In Alzheimer8217s Disease (6/4/2008). Madison C, Landau S, Cheung C, Lal R, Foster NL, Reiman EM, Koeppe RA, Weiner MW, Jagust WJ [Abstract]. Alzheimer's & Dementia, 4(2), T53.
Madison C, Landau S, Cheung C, Lal R, Foster NL, Reiman EM, Koeppe RA, Weiner MW, Jagust WJ (7/4/2008). Meta-Analysis ROIs And Minimal Deformation Templates Improve FDG-PET As a Candidate Biomarker In Alzheimer's Disease [Abstract]. Alzheimer's Dement, 4(2), T53.
Reiman EM, Chen K, Ayutyanont N, Lee W, Bandy D, Reschke C, Alexander GE, Weiner MW, Koeppe RA, Foster NL, Jagust WJ (7/4/2008). Twelve-month cerebral metabolic declines in probable Alzheimer’s disease and amnestic mild cognitive impairment: Preliminary findings from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) [Abstract]. Alzheimer's Dement, 4(2), T28, T110-11.
Lee W, Langbaum JBS, Chen K, Recshke C, Bandy D, Alexander GE, Foster NL, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM (7/4/2008). Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative [Abstract]. Alzheimer's Dement, 4(2), T23, T379.
Ayutyanont N, Chen K, Liu X, Reschke C, Lee W, Bandy D, Alexander GE, Jagust WJ, Koeppe RA, Foster NL, Reiman EM (7/4/2008). Differentiating amnestic MCI converting to probable AD from stable amnestic MCI using FDG-PET and an AD-related hypometabolism overlap index [Abstract]. Alzheimer's Dement, 4(2), T38.
Ayutyanont N, Chen K, Liu X, Reschke C, Lee W, Bandy D, Alexander GE, Jagust WJ, Koeppe RA, Foster NL, Reiman EM (7/4/2008). Differentiating amnestic mild cognitive impairment converting to probable Alzheimer's disease from stable amnestic mild cognitive impairment using FDG-PET and an Alzheimer's disease-related hypometabolism overlap index [Abstract]. Alzheimer's Dement, 4(2), T312.
Sadeghi N, Foster NL, Wang AY, Minoshima S, Lieberman AP, Tasdizen T (7/04/2008). Automatic Diagnostic Classification of Dementia with FDG-PET Using a Spatial Decision Tree Approach [Abstract]. Alzheimer's Dement, 4(2), T28, T387.
Fletcher PT, Wang AY, Foster NL, Joshi SC (7/4/2008). Quantifying Metabolic Asymmetry in Alzheimer's Disease Using Both MR and PET Imaging [Abstract]. Alzheimer's Dement, 4(2), T79, T286.
Zamrini E, Levy JA, Chelune GJ, Wang AY, Thorgusen S, Franchow EI, Card S, Foster NL (7/4/2008). Judgement of Line Orientation and FDG-PET Parietal Metabolism [Abstract]. Alzheimer's Dement, 4(2), T36,T400.
Levy JA, Chelune GJ, Wang AY, Thorgusen S, Franchow EI, Card S, Zamrini E, Foster NL (7/1/2008). Lateralized Associations Between Neuropsychological Functioning and Cerebral Glucose Metabolism [Abstract]. Alzheimer's Dement, 4(2), T52, T380.
Chelune GJ, Levy JA, Wang AY, Thorgusen S, Card S, Franchow EI, Zamrini E, Foster NL (7/1/2008). Correlates of Memory For High and Low Associative Content [Abstract]. Alzheimer's Dement, 4(2), T13, T552.
Foster NL, Wang AY, Levy JA, Koeppe RA, Jagust WJ, Chen K, Reiman EM, Weiner MW (7/1/2008). Frequency of Hemispheric Metabolic Asymmetry in Probable Alzheimer's Disease [Abstract]. Alzheimer's Dement, 4(4), T47, T286-7.
Hills WL, Warner JAE, Katz BJ, Chelune GJ, Foster NL, Steffens J, Thulin P, Chin S, Digre KB (2008). Neuro-ophthalmic Findings that may Reliably Differentiate PSP and Parkinson's Disease [Abstract]. North American Neuro-Ophthalmology Society (NANOS) Annual Meeting Proceedings,.
Hills WL, Warner JAE, Katz BJ, Chelune GJ, Foster NL, Steffens J, Thulin P, Chin S, Digre KB (6/1/2008). Differentiating Neuro-ophthalmic Findings in Progressive Supranuclear Palsy vs. Parkinson's Disease [Abstract]. International Neuro-Ophthalmology Society (INOS) Conference Proceedings.
Sadeghi N, Foster NL, Wang AY, Minoshima S, Lieberman A, Tasdizen T (2008). Automatic Classification of Alzheimer's Disease vs. Frontotemporal Dementia: A spatial decision tree approach with FDG-PET [#1037] [Abstract]. International Symposium on Biomedical Imaging (ISBI) Conference Proceedings (Online).
Madison C, Landau S, Lal R, Cheung C, Foster NL, Reiman E, Koeppe RA, Weiner M, Jagust W (2008). Use of MetaROIs and Minimal Deformation Templates to identify FDG PET Biomarker Regions in Alzheimer's Disease [Abstract]. Human Brain Mapping (Online).
Chen K, Ayutyanont N, Reschke C, Lee W, Alexander G, Bandy D, Langbaum J, Foster N, Weiner M, Koeppe R, Jagust W, Reiman E (2008). Application of an Alzheimer's disease hypometabolism index to FDG-PET [Abstract]. ADNI. J Nucl Med, 49(1), 23.
Chen K, Liu X, Zhou Y, Bandy D, Yu M, Keppler J, Klunk W, Mathis C, Foster N, Weiner M, Koeppe R, Jagust W, Reiman E (2008). An accurate and computationally efficient method for voxel-by-voxel estimation of the Pittsburgh compound B distribution volume ratio [Abstract]. ADNI. J Nucl Med, 49(1), 23.
Landau SM, Madison C, Cheung C, Reiman E, Foster NL, Jagust WJ (2008). Comparing Rates of Change in Cognitive Measurements and Regional Glucose Metabolism in Alzheimers Disease and Mild Cognitive Impairment: Data from the Alzheimers Disease Neuroimaging Initiative [Abstract]. Neurology, 70(S1), A447.
Hills WL, Warner J, Katz B, Chelune GJ, Foster NL, Steffens J, Thulin P, Chin S, Digre K (2008). Neuro-Ophthalmic Findings That May Reliably Differentiate Progressive Supranuclear Palsy and Parkinsons Disease [Abstract]. Neurology, 70(S1), A263.
Foster NL, Wang AY, Tasdizen T, Chen K, Jagust W, Koeppe RA, Reiman E, Weiner MW, Minoshima S (2008). Cerebral hypometabolism suggesting frontotemporal dementia in an Alzheimer’s disease clinical trial [PLATFORM PRESENTATION] [Abstract]. Neurology, 70(S1), A103.
Madison CM, Landau SM, Lal RA, Cheung C, Foster NL, Reiman ER, Weiner MW, Jagust WJ (2007). A new technique for generating functionally defined meta-analysis rois (metarois) to study FDG uptake in Alzheimer’s disease [Abstract]. Abstracts - Society for Neuroscience, 2007. Online, Program No. 104.6/BBB5.
Landau SM, Madison CM, Lal RA, Cheung C, Foster NL, Weiner MW, Reiman EM, Jagust WJ (2007). Region-specific longitudinal changes in cerebral glucose metabolism in Alzheimer’s disease and Mild Cognitive Impairment [Abstract]. Abstracts - Society for Neuroscience, 2007. Online, Program No. 889.5/01.
Levy JA, Chelune GJ, Zamrini E, Hoffman JM, Wang AY, Foster NL (2007). Pattern of word generation differs in frontotemporal dementia and Alzheimer’s disease [Abstract]. J Int Neuropsychol Soc, 13(S1), 100.
Chen K, Reiman EM, Alexander GE, Smilovici O, Lee W, Reschke C, Bandy D, Foster NL, Weiner MW, Koeppe RA, Jagust WJ (2007). The pattern and severity of FDG PET abnormalities in Alzheimer’s disease and amnestic Mild Cognitive Impairment: Preliminary findings from the Alzheimer’s Disease Neuroimaging Initiative [Abstract]. Alzheimer's & Dementia, 3((S1)), S103-4.
Fletcher PT, Wang AY, Tasdizen T, Chen K, Jagust WJ, Koeppe RA, Reiman EM, Weiner MW, Minoshima S, Foster NL (2007). Variability of Normal Cerebral Glucose Metabolism from the Alzheimer’s Disease Neuroimaging Initiative (ADNI): Implications for Clinical Trials [Abstract]. Annals of Neurology, 62(S11), S52.
Reiser RH, Chin SS, Gambetti P, Foster NL (2007). Clinical Features in a Patient with Late-Onset Sporadic VV1 Subtype Creutzfeldt-Jakob Disease [Abstract]. Annals of Neurology, 62(S11), S27.
Heidebrink JL, Gabel MJ, Higdon R, Foster NL, for the Pilot Collaborative PET Imaging Trial (). Validation of a consensus panel approach to dementia diagnosis [ICAD abstract P2-090] [Abstract]. Alzheimers Dement, 2(Suppl 1), S259.
Levy JA, Foster NL, Putnam KT, Seichepine DR, McGee L, Grimley M, Plumb T, Hammond CJ, Sunderland T (2006). Altered semantic processing in healthy older adults at risk for Alzheimer's disease [Abstract]. Alzheimers Dement, 2, S224.
Foster NL, Koeppe RA, Heidebrink JL, Stevenson V, VanHuysen C (2006). Quality assurance in a multi-center PET imaging trial. (Pilot Collaborative PET imaging Trial) [Abstract]. Alzheimers Dementia, 2, S322.
Foster NL, Plassman B, Langa K, Fisher GG, Giordani B, Wallace R (2006). Factors influencing the frequency of dementia evaluations in a population-representative sample in the United States.í [Abstract]. Alzheimers Dementia, 2, S262.
Foster NL (). Imaging Alzheimer’s Disease and Other Dementias with PET [Abstract #IM-09, presented at the Alzheimer's Association International Conference on Prevention of Dementia: Early Diagnosis and Intervention] [Abstract]. Alzheimers Dement, 1(Suppl), S5.
Foster NL (). FDG PET in the diagnosis of frontotemporal dementia [Abstract]. Biol Psychiatry, 57, 4S.
Mordhorst MJ, Guidotti L, Langenecker SA, Caveney AK, Persad CC, Bieliauskas, Foster NL, Giordani B (2005). Evidence of a Unique Contribution of Depression on Memory Function in a Clinical Sample [Abstract]. J Int Neuropsychol Soc, 11.
Heidebrink JL, Arnold SE, Barbas NR, Clark CM, DeCarli CS, Jagust WJ, Turner RS, Higdon R, Koeppe RA, Foster NL (2004). Diagnostic confidence in the clinical diagnosis of frontotemporal dementia and Alzheimer's disease [Abstract]. Ann Neurol, 56(Suppl 8), S19.
Foster NL, Barbas NR, Heidebrink JL, Turner RS, Clark CM, Jagust WJ, Arnold SE, DeCarli CS, Koeppe RA, Higdon R (2004). Adding FDG-PET to clinical information improves the accuracy of dementia diagnosis [Abstract]. Neurobiol Aging, 25, S372.
Heidebrink JL, Barbas NR, Turner RS, Clark CM, Jagust WJ, Arnold SE, DeCarli CS, Koeppe RA, Higdon R, Foster NL (2004). FDG-PET improves differential diagnosis of dementia when clinical history and examination are ambiguous [Abstract]. Neurobiol Aging, 25, S370-S371.
Foster NL, Nichols T, Koeppe RA, Giordani B, Kuhl D, Minoshima S, Lieberman A (2004). The topographic progression of glucose hypometabolism in definite Alzheimer's disease [Abstract]. Neurobiol Aging, 25, S291-S292.
Foster NL, Koeppe RA, Rogers V, Minoshima S, Clark CM, Jagust WJ, Arnold SA, Barbas NR, DeCarli CS, Heidebrink JL, Turner RS (2004). A multi-center trial to evaluate the clinical utility of FDG-PET [Abstract]. Neurobiol Aging, 25, 246.
Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA (2002). PET and treatment response in Alzheimer's disease [Abstract]. Neurobiol Aging, 23(1S), S563.
Takao M, Piccardo P, Murrell J, Miravalle L, Vidal R, Brashear A, Farlow M, Unverzagt F, Connelally M, Foroud T, Glazier B, Ghetti B, Foster N, Towfighi J, Koto A, Hulette C, Cochran E (2002). Neuropathologic heterogeneity associated with presenilin 1 gene mutations [Abstract]. Neurobiol Aging, 23, S417.
Aisen PS, Schafer K, Grundman M, Farlow M, Sano M, Jin S, Thomas R, Thal L, for the Alzheimers Disease Cooperative Study Foster NL, et al (2002). Results of a mulitcenter trial of rofecoxib and naproxen in Alzheimer's disease [Abstract]. Neurobiol Aging, 23, S429.
Foster NL, Heidebrink JL, Clark CM, et al (2002). Inter-rater reliability and diagnostic accuracy of FDG-PET is superior to clinical history and examination in dementia [Abstract]. Neurobiol Aging, 23, S353.
Langa K, Herzog AR, Foster NL, et al (2002). Out-of-pocket health care expenditures among elderly individuals with dementia in the United States [Abstract]. Neurobiol Aging, 23, 171.
Bozoki A, An HG, Foster NL, Giordani B, Little RJA (2002). Are there cognitive plateaus in Alzheimer's disease? [Abstract]. Neurobiol Aging, 23, S40.
Peltier AC, Reading PH, Beydoun A, Edwards J, Gambetti P, Foster NL (2002). Two concurrent cases of early-onset sporadic Creutzfeldt-Jakob disease in Michigan [Abstract]. Neurology, 58(Suppl 3), A442.
Foster NL, Poynter JA, Heidebrink JL, Jagust WJ, Clark CM, Turner RS, Barbas NR, Arnold SE, DeCarli C, Koeppe RA, Higdon R, Minoshima S (2002). Good diagnostic inter-rater reliability in a multicenter study of FDG-PET in the evaluation of dementia [Abstract]. Neurology, 58(Suppl 3), A401.
Hong M, Shah GV, Adams KM, Turner RS, Foster NL (2002). Spontaneous intracranial hypotension causing reversible frontotemporal dementia [Abstract]. Neurology, 58(Suppl 3), A380.
Murrell JR, Miravalle L, Foster NL, Albin R, Takao M, Ghetti B (2001). Early-onset familial Alzheimer disease from the first American report: a presenilin-1 (PS1) mutation found in descndents [Abstract]. J Neuropathol Exp Neurol, 60, 543.
Langa KM, Kabeto M, Herzog AR, Foster NL, Straus W, Fendrick AM (2001). Dementia and psychiatric illness as predictors of nursing home admission: results from a nationally representative sample of U.S. elderly [Abstract]. Journal of General Internal Medicine, 16(Suppl 1), 150.
Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE (2001). Metabolic and pathologic discordance in very early Alzheimer's disease: pathophysiological implications [Abstract]. Neurobiol Aging, 22, 340.
Moretti PM, Giordani B, Kluin KJ, Minoshima S, Kuhl DE, Seltzer WK, Foster NL (2000). Early-onset familial Alzheimer's disease and spastic paraparesis associated with a novel insertional mutation of the presenilin 1 gene [Abstract]. Neurobiol Aging, 21, S175.
Makoni S, Ferreira M, Foster NL (2000). Investigating linguistic and cultural constructions of late-life dementias in urban black Africans [Abstract]. Neurobiol Aging, 21, S170.
Foster NL, Moura V, Giordani B, Minoshima S, Kuhl DE (2000). Frontal hypometabolism in mild Alzheimer's disease is associated with more rapid progression of dementia [Abstract]. Neurobiol Aging, 21, S108.
Berent S, Giordani B, Minoshima S, Foster NL, Koeppe RA, Kuhl DE (1999). Psychological disturbance and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease [Abstract]. J Cereb Blood Flow Metab, 19(Suppl 1), S21.
Minoshima S, Kuhl DK, Cross DJ, Buchtel HA, Pennell PB, Giordani B, Berent S, Foster NL, Ross DA, Henry TR (1999). Does the entorhinal pathology explain the discordance between glucose metabolic and pathologic changes in very early Alzheimer's disease? [Abstract]. J Cereb Blood Flow Metab, 19(Suppl 2), S4.
Foster NL, Moura V, Gelb DJ, Sima AAF (1999). Consensus clinical criteria have limited ability to distinguish dementia with Lewy bodies and Alzheimer's disease [Abstract]. Neurology, 52(Suppl 2), A476.
Bozoki A, Giordani B, Heidebrink JL, Carr JM, Foster NL, Berent S (1999). Relevance of mild cognitive impairments to prediction of Alzheimer's disease among isolated memory Impairment patients [Abstract]. Neurology, 52(Suppl 2), A386.
Minoshima S, Cross DJ, Foster NL, Henry TR, Kuhl DE (1999). Discordance between traditional pathologic and energy metabolic changes in very early Alzheimer's disease. Pathophysiological implications [Abstract]. Ann N Y Acad Sci, 893, 350-2.
Shaw BA, Connell CM, Holmes SB, Foster NL (1998). Attitudes toward participation in Alzheimer's disease research among family caregivers [Abstract]. Gerontologist, 38(Special Issue 1), 388.
Doody R, Clark C, Farlow M, Foster NL, Gonzales N, Liao J, Lai E, Massman P (1998). Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients [Abstract]. Neurobiol Aging, 19, S303.
Foster NL, Sima AAF, Minoshima S, Kuhl DE (1998). Clinical and neuropathological correlations with PET in FTDP-17 and sporadic frontal dementia [Abstract]. Neurobiol Aging, 19, S296.
Nishimura S, Minoshima S, Giordani B, Johanns J, Little RJA, Foster NL, Kuhl DE (1998). Predicting cognitive decline in Alzheimer's disease using positron emission tomography [Abstract]. J Nucl Med, 39, 96P.
Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1998). [F-18]FDG PET predicts the development of Alzheimer's disease in memory impaired patients without dementia [Abstract]. J Nucl Med, 39, 96P.
Lajiness-ONeill R, Giordani B, Berent S, Minoshima S, Foster N, Koeppe R, Kuhl D (1998). Paradoxical increase in frontal cerebral glucose utilization in isolated memory impairment at a two-year follow-up: relationship to neuropsychological functioning [Abstract]. Journal of the International Neuropsychological Society, 4, 44.
Fisher NJ, Rourke BP, Bieliauskas LA, Foster NL (1998). External validation of distinct neuropsychological subgroups of Alzheimer's disease patients: preliminary findings from the CERAD data [Abstract]. Journal of the International Neuropsychological Society, 4, 30.
Heidebrink JL, Foster NL (1997). Alzheimer's disease is particularly underreported in women and minorities [Abstract]. Gerontologist, 37(Special Issue 1), 22-23.
Heidebrink JL, Giordani B, Mellow AM, Johanns JR, Little RJA, Foster NL (1997). Phenobarbital does not reduce the adverse effects of low-dose ketamine [Abstract]. Ann Neurol, 42, 403.
Heidebrink JL, Minoshima S, Giordani B, Mellow AM, Johanns JR, Little RJA, Foster NL (1997). Behavioral effects of ketamine can not be explained by cingulate activation [Abstract]. Ann Neurol, 42, 403.
Gilman S, Foster NL, Koeppe RA, Kilbourn MR, et al (1997). Striatal monoaminergic presynaptic terminals in Alzheimer's disease studied with (+)[11C]dihydrotetrabenazine and positron emission tomography [Abstract]. J Neurol Sci, S150, S21.
Fisher NJ, Rourke BP, Bieliauskas LA, Giordani B, Berent S, Foster NL (1997). Neuropsychological subgroups of patients with Alzheimer's disease: case presentations [Abstract]. Canadian Psychology, 38, 10.
Heidebrink JL, Millett SL, Jones MZ, Foster NL, for the Michigan Dementia Postmortem Network (1997). Differences between Alzheimer's disease in the community and at an academic referral center [Abstract]. J Neuropathol Exp Neurol, 56, 618.
Foster NL, Minoshima S, Sima AAF, Kuhl DE (1997). Variability of cerebral glucose metabolic patterns in Alzheimer's disease can not be explained by coexistent disorders [Abstract]. J Cereb Blood Flow Metab, 17(Suppl 1), S578.
Minoshima S, Foster NL, Frey KA, Albin RL, Sima AAF, Berent S, Kuhl DE (1997). Metabolic differences in Alzheimer's disease with and without cortical Lewy bodies as revealed by PET [Abstract]. J Cereb Blood Flow Metab, 17(Suppl 1), S437.
Minoshima S, Foster NL, Frey KA, Wahl RL, Burdette JH, Kuhl DE (1997). Can FDG PET distinguish dementia patients with cortical Lewy bodies from pure Alzheimer's disease? [Abstract]. J Nucl Med, 38(Suppl), 70P-71P.
Kluin DJ, Gilman S, Foster NL, Sima AAF, DAmator C, Bruch LA, Bluelein L, Little RJ, Johanns J (1997). Degeneration of substantia nigra pars compacta contributes to the dysarthria of PSP [Abstract]. Neurology, 48(Suppl 2), A97.
Gilman S, Foster NL, Minoshima S, Koeppe RA, Martorello SP, Heumann ML, Kuhl DE (1997). Benzodiazepine receptor density in progressive supranuclear palsy studies with [11C]flumazenil and PET [Abstract]. Mov Disord, 12(suppl 1), 78.
Giordani B, Persad CC, Mesmer C, Sima AAF, Gilman S, Albin RL, Foster NL, Heumann ME, Kluin K, Berent S (1997). Lewy body disease differs from Alzheimer's disease in neuropsychological profile [Abstract]. Journal of the International Neuropsychological Society, 3, 15.
Whall A, Black M, Yankou D, Groh C, Foster NL (1996). Effects of natural elements upon agitation in dementia [Abstract]. Gerontologist, 36(Special Issue 1), 23-24.
Heidebrink JL, Gombosi E, Cornellier DS, LeWitt PA, Foster NL (1996). Do satellite diagnostic and treatment centers overcome referral bias in dementia research? [Abstract]. Ann Neurol, 40, 502.
Sima AAF, Foster N, Jones MZ, DAmato C, Boyer PF (1996). Mesocorticolimbic dementia: DLBD without Lewy bodies or a separate entity? [Abstract]. J Neuropathol Exp Neurol, 5, 609.
Minoshima S, Giordani BL, Berent S, Frey KA, Foster NL, Kuhl DE (1996). The posterior cingulate cortex: the earliest metabolic reduction in Alzheimer's disease as revealed by PET [Abstract]. J Nucl Med, 37, 164P.
Minoshima S, Frey KA, Giordani BL, Foster NL, Koeppe RA, Berent S, Albin RL, Kuhl DE (1996). Technical feasibility and initial diagnostic application of functional brain image database system in dementia [Abstract]. J Nucl Med, 37, 163P.
Grundman M, Petersen RC, Ernesto C, Galasko D, Sano M, Thal LJ, the ADCS Cooperative Study Foster NL, et al (1996). Rate of Dementia of the Alzheimer Type (DAT) in subjects with mild cognitive impairment [Abstract]. Neurology, 46, A403.
Foster NL, Sima AAF, DAmato C, Bruch LA, Kluin K, Bluemlein LA, Little RJ, Johanns J, Gilman S (1996). Cerebral cortical pathology in progressive supranuclear palsy is correlated with severity of dementia [Abstract]. Neurology, 46, A363.
Galasko D, Bennett D, Ernesto C, Thomas R, Sano M, Alzheimers Disease Cooperative Study Foster NL, et al (1996). Development of a pool of items to assess activities of daily living in clinical trials for Alzheimer's disease [Abstract]. Neurology, 46, A248.
Sano M, Growdon J, Thomas R, Ernesto C, Schafer K, Woodbury P, Grundman M, Thal L, Alzheimers Disease Cooperative Study Foster NL, et al (1996). Evaluation of efficacy measures in clinical trials for Alzheimer's disease: does psychometric test performance predict clinically relevant outcomes? [Abstract]. Neurology, 46, A218.
Fisher NJ, Rourke BP, Bieliauskas L, Giordani B, Berent S, Foster NL (1996). Neuropsychological subgroups of patients with Alzheimer's disease [Abstract]. Journal of the International Neuropsychological Society, 2, 30.
Bartok JA, Wilson CS, Giordani B, Foster N, Berent S (1996). Longitudinal investigation of response bias, recall and recognition in Alzheimer's disease [Abstract]. Journal of the International Neuropsychological Society, 2, 13.
Sano M, Ernesto C, Klauber M, Schafer K, Woodbury P, Grundman M, Thal L, Alzheimers Disease Cooperative Study Foster NL, et al (1996). Using the ADAS to assess change among moderately and severly impaired AD patients [Abstract]. Journal of the International Neuropsychological Society, 2, 13.
Buchtel HA, Koeppe RA, Mountz J, Foster NL, Berent S, Giordani B, Kuhl DE (1995). Cerebral blood flow changes in response to visual stimulation in demented patients [Abstract]. Abstracts - Society for Neuroscience, 21, 1488.
Foster NL, Minoshima S, Kuhl DE, Sima AAF (1995). Metabolic topography of progressive limbic lobe sclerosis [Abstract]. J Cereb Blood Flow Metab, 15, S818.
Minoshima S, Foster NL, Frey KA, Kuhl DE (1995). Abnormal energy metabolism in the cingulate cortex in Alzheimer's disease [Abstract]. J Cereb Blood Flow Metab, 15, S790.
Kuhl DE, Fessler JA, Minoshima S, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA (1995). In vivo mapping of the vesicular acetylcholine transporter in aging and Alzheimer's disease [Abstract]. J Cereb Blood Flow Metab, 15, S132.
Berent S, Giordani B, Minoshima S, Foster NL, Koeppe RA, Kuhl DE (1995). Isolated Memory Impairment (IMI): relationship to cognition, brain metabolism and Alzheimer's disease [Abstract]. J Cereb Blood Flow Metab, 15, S102.
Sima AAF, DAmato C, Foster NL, Lynchj T, Defendini R, Wilhelmsen KC (1995). Neuronal and glial inclusions in familial progressive limbic lobe sclerosis [Abstract]. J Neuropathol Exp Neurol, 54, 459.
Sano M, Growdon J, Klauber M, Ernesto C, Schafer K, Woodbury P, Grundman M, Thal L, Alzheimers Disease Cooperative Study Foster NL, et al (1995). Expanding the severity range of patients in clinical trials for Alzheimer's disease: a multicenter clinical trial of selegiline and alpha-tocopherol [Abstract]. Neurology, 45(Suppl 4), A289.
Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJA, Foster NL (1995). Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease [Abstract]. Neurology, 45, A253.
Bartok JA, Wilson CS, Giordani B, Keys BA, Foster NL, Persad CC, Berent S (1995). Patterns of recall and recognition deficits dependent on Alzheimer's disease severity [Abstract]. Journal of the International Neuropsychological Society, 1, 161.
Roper BL, Giordani B, Berent S, Persad CC, Bieliauskas LA, Holleran K, Foster NL, Gilman S (1995). Relationship of cognitive impairment and depression in motor disabilities in Parkinson's disease [Abstract]. Journal of the International Neuropsychological Society, 1, 153.
Sima AAF, DAmato C, Defendini RF, Jones MZ, Foster NL, Lynch T, Wilhelsen KC (1994). Primary limbic lobe gliosis: familial and sporadic cases [Abstract]. Brain Pathol, 4, 438.
Murman DL, Frey KA, Knesper DJ, Giordani B, Berent S, Kuhl DE, Foster NL (1994). Clinical and neuropsychometric predictors of progression in patients with complaints of memory loss [Abstract]. Ann Neurol, 36, 311.
Zubieta JK, Frey KA, Koeppe RA, Kilbourn MR, Mulholland GK, Foster NL, Kuhl DE (1994). Muscarinic receptor binding in aging and Alzheimer's disease determined with [C-11]N-methyl-4-piperidyl benzilate and PET [Abstract]. J Nucl Med, 35, 20P.
Holmes SB, Foster NL, Connell CM (1993). Satellite diagnostic and treatment centers: evaluation of a staff training program [Abstract]. Gerontologist, 33(special issue 1), 198.
Morgan MC, McCune WJ, Foster NL, Brunberg J, Berent S, Kuhl D (1993). Correlations between positron emission tomography (PET) and magnetic resonance imaging (MRI) in lupus patients with and without dementia [Abstract]. Arthritis and Rheumatism, 36, S87.
Hara M, Minoshima S, Foster NL, Kuhl DE (1993). Is regional cerebral blood flow coupled with glucose metabolism in Alzheimer's disease? [Abstract]. J Nucl Med, 34, 116P.
Groom GN, Junck L, Foster NL, Frey KA, Kuhl DE (1993). Positron emission tomography of [C-11]PK 11195 binding to peripheral benzodiazepine receptors in Alzheimer's disease [Abstract]. J Nucl Med, 34, 116P.
Groom GN, Koeppe RA, Foster NL, St Laurent R, Giordani BJ, Kuhl DE (1993). The effect of age of onset on regional cerebral glucose metabolism in Alzheimer's disease [Abstract]. J Nucl Med, 34, 4P.
Wolf FM, Sharpe PA, Robins LS, Zweiffler AJ, Shope JT, Foster NL (1993). Development of an early stage dementia helping relationship inventory [Abstract]. Professions Education Researcher Quarterly, 14, 11.
Mellow AM, Foster NL, Aronson SM, Giordani B, St Laurent RT, Berent S (1993). Behavioral effects of the NMDA antagonist, ketamine, in Alzheimer's disease [Abstract]. Biol Psychiatry, 33, 142A.
Sano M, Morris J, Thal L, Members of Alzheimers Disease Cooperative Study Foster NL, et al (1993). Developing outcome measures for clinical trials by the Alzheimer's Disease Cooperative Study (ADCS): standardized training for the clinical rating (CDR), initial results [Abstract]. Neurology, 43, A291.
Krishnan S, Foster NL, Trobe JD, Butter CM, Kuhl DE (1992). Visual impairments in patients with Alzheimer's disease correlate with reduced metabolism in visual association cortex measured by PET [Abstract]. Journal of the American Geriatrics Society, 40, SA13.
Giordani B, Berent S, Koeppe R, Foster N, Buchtel H, Boivin K, Frey K, Kuhl D (1992). Memory and cerebral metabolism in Parkinson's disease [Abstract]. J Clin Exp Neuropsychol, 14, 60-61.
DAmato CJ, Foster NL, Hicks SP, Sima AAF (1992). Swollen cortical neurons and Lewy bodies accompanying progressive supranuclear palsy and Creutzfeldt-Jakob disease [Abstract]. J Neuropathol Exp Neurol, 51, 324.
Fratkin J, Remick D, DAmato C, Hogan J, Shope J, Izenson S, Foster N, Huang T, Dragoc L, Garrein J, Ho K, Sima A, Lovell K, Jones M (1992). Michigan postmortem examination network for dementia patients [Abstract]. J Neuropathol Exp Neurol, 51, 315.
Meyer MA, Koeppe RA, Frey KA, Foster NL, Kuhl DE (1992). Benzodiazepine receptors are unaltered in hypometabolic parietal cortex in Alzheimer's disease [Abstract]. J Nucl Med, 33, 887.
Foster NL, Gilman S, Gelb DJ, Struble L, Giordani B, Berent S, Lohman M (1992). Extrapyramidal signs in probable Alzheimer's disease [Abstract]. Neurology, 42(Suppl 3), 215S.
Axelrod BN, Goldman RS, Giordani BJ, Foster NL, Berent S (1992). Longitudinal stability of the Fuld cholinergic profile in Alzheimer's disease [Abstract]. J Clin Exp Neuropsychol, 14, 21.
DAmato CJ, Sima AF, Foster NL, Dickson DW, Hicks SP (1991). Cerebral Lewy bodies with progressive supranuclear palsy [Abstract]. J Neuropathol Exp Neurol, 50, 308.
Fratkin JD, Jones MZ, DAmato CJ, Foster NL, Remick D, Dragovic L, Garcia JH, Ho KL, Huang TE, Sima A, Lovell K (1991). Michigan Dementia postmortem examination program: neuropathological efforts towards morphological standardization of dementia diagnoses [Abstract]. Journal of Neuropathology and Experimental Neurology, 50, 300.
Giordani B, Berent S, Koeppe RA, Foster NL, Buchtel HA, Kuhl DE, Frey KA, Lehtinen SJ (1991). PET-FDG cerebral metabolic indices of memory impairment [Abstract]. Biol Psychiatry, 29, 683S.
Chen JW, Foster NL, Giordani B, Harris J, Koeppe RA, Berent S, Kuhl DE (1991). The relationship of Mini-Mental State examination (MMSE) and cerebral glucose metabolism in Alzheimer's disease [Abstract]. Journal of the American Geriatrics Society, 39, A44.
Lee KS, Frey KA, Koeppe RA, Buck A, Mulholland GK, Foster NL, Kuhl DE (1991). Quantification of muscarinic cholinergic receptors in aging and Alzheimer's disease [Abstract]. J Nucl Med, 32, 942-943.
Foster NL, Giordani B, Mellow A, Aronson S, Berent S (1991). Memory effects of low dose ketamine in Alzheimer's disease [Abstract]. Neurology, 41(Suppl 1), 214.
Boivin MJ, Giordani B, Berent S, Amato DA, Lehtinen S, Koeppe RA, Buchtel HA, Foster NL, Kuhl DE (1991). Verbal fluency and positron emission tomographic mapping of regional cerebral glucose metabolism [Abstract]. J Clin Exp Neuropsychol, 13, 80-81.
Kluin KJ, Foster NL, Gilman S, Berent S (1990). Speech disorders in progressive supranuclear palsy [Abstract]. ASHA, 32, 122.
Hermanowicz NS, Penney JB, Foster NL, Shoulson I (1990). Muscarinic receptors in basal ganglia of progressive supranuclear palsy [Abstract]. Abstracts - Society for Neuroscience, 16, 1120.
Chen JW, Foster NL, Berent S, Mountz JM (1990). Single photon emission computed tomography with N-isopropyl-(I-123)p-iodoamphetamine (IMP-SPECT) fails to differentiate progressive from non-progressive dementia [Abstract]. Journal of the American Geriatrics Society, 38, A28.
Jones MZ, Douglass R, Fratkin JD, Foster NL, DAmato CJ, Izenson SB, Dingeldey CJ, Goodman CB, Beane GE (1990). Dementia postmortem examination program: interim recommendations for Michigan [Abstract]. J Neuropathol Exp Neurol, 49, 307.
Kluin KJ, Foster NL, Gilman S, Berent S (1990). Speech disorders in progressive supranuclear palsy [Abstract]. Neurology, 40(Suppl 1), 424.
Butter CM, Trobe JD, Foster NL, Berent S (1990). A new brief battery of tests for the detection of focal visuospatial deficits in the early stages of Alzheimer's disease [Abstract]. J Clin Exp Neuropsychol, 12, 21-22.
Hansen MS, Foster NL, Judge F, Berent S (1989). Cerebral glucose metabolism in a patient with neurosyphilis and response to treatment [Abstract]. Clin Res, 37, 974A.
Brenner HM, Foster NL, Amato D, Koeppe RA, Gilman S, Kuhl DE (1989). The ratio of cerebral glucose metabolism to cerebral blood flow in aged normal subjects and in Alzheimer's disease [Abstract]. Clin Res, 37, 973A.
Foster NL, Gilman S, Morin E, Markel D, Berent S (1989). The pattern of cerebral hypometabolism studied with positron emission tomography is similar in sporadic and familial Alzheimer's disease [Abstract]. Ann Neurol, 26, 135.
Foster NL, Mann U, Mohr E, Sunderland T, Katz D, Chase TN (1989). Focal cerebral glucose hypometabolism in definite Alzheimer's disease [Abstract]. Ann Neurol, 26, 132-133.
Mountz JM, Modell JG, Foster NL, DuPree ES, Ackerman RJ, Petry NA, Kuhl DE (1989). A model for outcome-prediction following stroke using the comparison of CT and HM-PAO SPECT [Abstract]. J Nucl Med, 30, 895.
Koeppe R, Foster NL, Kuhl D (1989). Tissue atrophy alone cannot explain parietal hypometabolism in PET studies of Alzheimer's disease [Abstract]. J Nucl Med, 30, 895.
Mountz JM, Modell JG, Foster NL, DuPree ES, Ackerman RJ, Petry N, Bluemlein LE, Kuhl DE (1989). Prognosis in stroke using the comparison of CT and 99mTc-HM-PAO SPECT [Abstract]. J Cereb Blood Flow Metab, 9(Suppl 1), S718.
Kuhl DE, Koeppe RA, Foster NL, Agranoff BW, Buchtel HA, Mountz JM (1989). Cerebral perfusion, metabolic, and transport relations in Alzheimer's and parkinsonian dementia [Abstract]. J Cereb Blood Flow Metab, 9(Suppl 1), S525.
Junck L, Moen JG, Bluemlein L, Foster NL, Agranoff BW, Gilman S, Young AB, Rothley JR, Betley AT, Koeppe RA, Hutchins G, Hichwa RD, Berent S, Kuhl DE (1989). Cerebral glucose metabolism in normal aging studied with PET [Abstract]. J Cereb Blood Flow Metab, 9(Suppl 1), S524.
Junck L, Moen JG, Foster NL, Gilman S, Kuhl DE (1989). Cerebellar metabolic asymmetry in degenerative neurological disorders studied with PET [Abstract]. Neurology, 39(Suppl 1), 164.
Hansen MS, Foster NL, Siegel GJ, Berent S, Kuhl DE (1988). Mesial and lateral temporal lobe glucose metabolism in aging [Abstract]. Clin Res, 36, 921A.
Aldrich MS, Foster NL, White RF, Bluemlein LA, Prokopowicz G (1988). Sleep abnormalities in progressive supranuclear palsy [Abstract]. J Sleep Res, 17, 271.
Stafford-Schuck KA, Mountz JM, Foster NL, Ackermann RJ, Petry NA, Kuhl DE (1988). Stroke prognosis using 99mTc-HM-PAO SPECT [Abstract]. J Nucl Med Tech, 16, A65.
Koeppe RA, Foster NL, Rothley JM, Kuhl DE (1988). Determination of rate constants from dynamic FDG PET studies in degenerative brain disorders [Abstract]. J Nucl Med, 29(Suppl 1), 915.
Mountz JM, Foster NL, Stafford-Schuck KA, Ackermann RJ, Petry NA, Kuhl DE (1988). Stroke prognosis using 99mTc HM PAO SPECT [Abstract]. J Nucl Med, 29(Suppl 1), 743.
Foster NL, Morin EM, Kuhl DE, Gilman S (1988). Glucose metabolic activity in the basal ganglion and thalamus differs in progressive supranuclear palsy and Alzheimer's disease [Abstract]. Neurology, 38(Suppl 1), 369.
Foster NL, Hansen MS, Siegel GJ, Kuhl DE (1988). Mesial and lateral temporal glucose metabolism in aging and Alzheimer's disease studied by PET [Abstract]. Neurology, 3(Suppl 1), 133.
Mountz JM, Foster NL, Ackermann RJ, Petry NA, Kuhl DE (1987). Utility of Tc-99m HM PAO in evaluation of stroke [Abstract]. Radiology, 165(Suppl), 244.
Townsend J, Foster NL, Siegel GJ, Salen G, Sadowsky M, Berginer VM (1987). Psychiatric manifestations of cerebrotendinous xanthomatosis [Abstract]. Ann Neurol, 22, 134.
Foster NL, Gilman S, Berent S, Brown MB, Hichwa RD (1987). Glucose hypometabolism in progressive supranuclear palsy not limited to frontal cortex [Abstract]. Ann Neurol, 22, 123.
Berent S, Foster NL, Gilman S, Hichwa R, Lehtinen S (1987). Patterns of cortical 18-F-FDG metabolism in Alzheimer's and progressive supranuclear palsy patients are related to the types of cognitive impairments [Abstract]. Neurology, 37(Suppl 1), 172.
Foster NL, Berent S, Brown MB, Gilman S, Hichwa RD (1987). Cerebral cortical metabolism reflects performance on the Wechsler adult intelligence scale [Abstract]. Neurology, 37(Suppl 1), 169.
Wilt JL, Foster NL, Hutchins GD, Rothman ED, Rothley JM, Hichwa RD (1986). A comparison of arterial versus arteriovenous sampling in the measurement of glucose metabolism by positron emission tomography [Abstract]. Clin Res, 34, 1011A.
Foster NL, Gilman S, Berent S, Hichwa RD (1986). Distinctive patterns of cerebral cortical glucose metabolism in progressive supranuclear palsy studied with positron emission tomography [Abstract]. Neurology, 36(Suppl 1), 338.
Foster NL, Chase TN (1986). Cerebral metabolic rate of glucose and Alzheimer's disease [Abstract]. J Cereb Blood Flow Metab, 6, 125.
Foster NL, VanDerSpek A, Sackellares JC, Aldrich MS, Hichwa RH, Gilman S, Agranoff BW (1985). The effect of diazepam sedation on cerebral glucose metabolism in Alzheimer's disease [Abstract]. Abstracts - Society for Neuroscience, 11, 1126.
Sheridan PH, Sato S, Foster NL, Bruno G, Fedio P, Chase TN (1985). Alpha background and parietal lobe function (positron emission tomography, psychometry) in Alzheimer's disease [Abstract]. Electroencephalogr Clin Neurophysiol, 61, 33P.
Tamminga CA, Tanimoto K, Foster NL, Chase TN (1985). Alzheimer's disease: somatostatin loss in area of maximal fluorodeoxyglucose reduction [Abstract]. Neurology, 35(Suppl 1), 183.
Martin A, Bouwers P, Lalonde F, Cox C, Foster NL, Chase TN, Fedio F (1984). Subgroups of Alzheimer's patients: neuropsychological and cerebral metabolic profiles [Abstract]. Abstracts - Society for Neuroscience, 10, 310.
Foster NL, Tamminga CA, ODonohue TL, Chase TN (1984). PET-directed study of neuropeptide Y in Alzheimer's disease [Abstract]. Abstracts - Society for Neuroscience, 10, 173.
Bruno G, Foster NL, Fedio P, Mohr E, Cox C, Gillespie MM, Chase TN (1984). THIP therapy of Alzheimer's disease [Abstract]. Neurology, 34(Suppl 1), 225.
Foster NL, Cox C, Harland AL, Fedio P, Chase TN (1983). Vasopressin in Alzheimer's disease (Reply) [Abstract]. Neurology, 33, 1635.
Pikus AT, Vernon EK, Grady CL, Foster NL, Sunderland T (1983). Audiologic profile in Alzheimer's disease [Abstract]. ASHA, 25, 134.
Grimes AM, Grady CL, Foster NL, Sunderland T (1983). Performance of the SSW in Alzheimer's disease [Abstract]. ASHA, 25, 134.
Foster NL, Chase TN (1983). Relative preservation of frontal glucose metabolism in early Alzheimer's disease [Abstract]. Abstracts - Society for Neuroscience, 9, 270.
Foster NL, Newman RP, LeWitt PA, Gillespie MM, Chase TN, Larsen TA (1983). Beta-blockade of parkinsonian tremor [Abstract]. Ann Neurol, 14, 134.
Foster NL, Hare TA, Chase TN (1983). Spinal fluid GABA in Alzheimer's disease [Abstract]. Neurology, 33(Suppl 2), 68.
Foster NL, Chase TN, Patronas NJ, Brooks RL, DiChiro G, Fedio P (1982). Cerebral mapping of apraxia by positron emission tomography in Alzheimer's disease [Abstract]. Ann Neurol, 12, 89.
Newman RP, LeWitt PA, Raphaelson MI, Foster NL, Calne DB, Chase TN (1982). Dystonia: therapy with dopaminergic ergot derivatives [Abstract]. Ann Neurol, 12, 82.
Foster NL, Chase TN, Hare TA (1982). THIP treatment of Huntington's disease [Abstract]. Neurology, 32, A206.
LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster NL, Dambrosia J, Calne DB (1982). Comparison of pergolide and bromocriptine therapy in parkinsonism [Abstract]. Neurology, 32, A181.
Foster NL, Patronas NJ, DeLaPaz R, DiChiro G, Brooks R, Chase TN, Fedio P, DeNaro A, Durso R (1982). PET studies of Alzheimer's disease [Abstract]. Neurology, 32, A167.

Other

Foster NL, Denton R, Alderman K (). A Guide to Guardianship Medical Evaluations: A Utah Perspective. Utah Physician (pp. 22-23).
Hong M, Shah GV, Adams KM, Turner RS, Foster NL (2003). Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Dementia Review Series (5, pp. 9-11).
Foster NL (1991). The clinical diagnosis of Alzheimer's disease. Michigan Postgraduate Review (8, pp. 107-113).

Report

Messner D, Rabins P with substantive review and feedback from Alzheimers Initiative Working Group Amerongen D, Downing AC, Foster N, Keenan A, Payzant E, Schneider L (). Designing Late Phase Clinical Trials of Disease-modifying Agents to Delay or Prevent Dementia due to Alzheimer's Disease. Available: http://www.cmtpnet.org/docs/resources/Alzheimer_Report_REVISED_FINAL_1.pdf. Baltimore: CMTP's Green Park Collaborative Initiative.

Video/Film/CD/Web/Podcast

Foster NL, Garcia-Leavitt E (). Improving the quality of life for Alzheimer's patients through early diagnosis [Web]. Salt Lake City: KSL. Available: http://www.ksl.com/index.php?sid=35790114&nid=148&title=improving-the-quality-of-life-for-alzheimers-patients-through-early-diagnosis.
Foster NL (). Proactive Management of Cognitive Health in Patients with Diabetes [Web]. Laramie: Wyoming Geriatric Education Center, University of Wyoming. Available: wygec.adobeconnect.com.
Foster NL (). What do we know about the initial triggers for Alzheimer's disease? [Video]. Salt Lake City: ABC. Available: Hot Topics series.

Service

04/27/2018

Interviewee

top 10 most viewed article releases of 2018: "Music activates regions of the brain spared by Alzheimer's disease"

Global

Foster, Norman L., MD

Chief, Division of Cognitive Neurology

Clinical Locations

Specialties

Board Certification and Academic Information

Patient Rating

Patient Comments

Academic Locations

650 Komas

Board Certification and Academic Information

Research Interests

Education History

Selected Publications - Journal Articles

Journal Article

Review

Book Chapter

Conference Proceedings

Editorial

Letter

Abstract

Other

Report

Video/Film/CD/Web/Podcast

Global Impact

Service

IMPACT 2

AbbVie M15-566

IMPACT

SUVN-502

Biogen BIIb037 (CLARITY)

News Articles

Music Activates Regions of the Brain Spared by Alzheimer’s Disease

Music and the Mind: Opera Diva Renée Fleming & U Neurologists Explore the Healing Power of Music

Alzheimer’s Caregivers Need Support, Too

An Alzheimer's Program for the 21st Century: Top Expert to Open Clinic at U of U, Join New Brain Institute

The Scope Health Sciences Radio